

1 **Genome-wide analysis of heart failure yields insights into disease**

2 **heterogeneity and enables prognostic prediction in the Japanese population**

3
4 **Authors:** Nobuyuki Enzan¹⁻³, Kazuo Miyazawa¹, Satoshi Koyama^{1,2,4}, Ryo Kurosawa¹, Hirotaka
5 Ieki^{1,5}, Hiroki Yoshida^{1,6}, Fumie Takechi^{1,7}, Masashi Fukuyama^{1,6}, Ryosuke Osako^{1,8}, Kohei
6 Tomizuka⁹, Xiaoxi Liu⁹, Kouichi Ozaki^{1,10}, Yoshihiro Onouchi^{1,11}, BioBank Japan Project,
7 Koichi Matsuda¹², Yukihide Momozawa¹³, Hiroyuki Aburatani¹⁴, Yoichiro Kamatani¹⁵, Takanori
8 Yamaguchi⁸, Akazawa Hiroshi⁶, Koichi Node⁸, Patrick T. Ellinor^{2,3,16}, Michael G. Levin^{17,18},
9 Scott M. Damrauer^{18,19}, Benjamin F. Voight²⁰⁻²², Jacob Joseph^{23,24}, Yan V. Sun^{25,26}, Chikashi
10 Terao⁹, Toshiharu Ninomiya²⁷, Issei Komuro^{28,29} and Kaoru Ito^{1*}

11 **Affiliations:**

12 1. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative
13 Medical Sciences, Yokohama, Japan.

14 2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.

15 3. Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA,
16 USA.

17 4. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT,
18 Cambridge, MA, USA.

19 5. Department of Genetics, Stanford University School of Medicine, Stanford, USA.

20 6. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of
21 Tokyo, Tokyo, Japan.
22

- 23 7. Department of pediatrics Graduate School of Medical and Pharmaceutical Sciences, Chiba
- 24 University, Chiba, Japan.
- 25 8. Department of Cardiovascular Medicine, Saga University, Saga, Japan.
- 26 9. Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical
- 27 Sciences, Kanagawa, Japan.
- 28 10. Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology,
- 29 Obu, Japan.
- 30 11. Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan.
- 31 12. Laboratory of Clinical Genome Sequencing, Department of Computational Biology and
- 32 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo,
- 33 Japan.
- 34 13. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences,
- 35 Kanagawa, Japan.
- 36 14. Genome Science Division, Research Center for Advanced Science and Technology, The
- 37 University of Tokyo, Tokyo, Japan.
- 38 15. Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical
- 39 Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- 40 16. Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, MA,
- 41 USA.
- 42 17. Division of Cardiovascular Medicine, Perelman School of Medicine, University of
- 43 Pennsylvania, Philadelphia, PA, USA.
- 44 18. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.

- 45 19. Department of Surgery, University of Pennsylvania Perelman School of Medicine,
46 Philadelphia, PA, USA.
- 47 20. Department of Genetics, University of Pennsylvania Perelman School of Medicine,
48 Philadelphia, PA, USA.
- 49 21. Department of Systems Pharmacology and Translational Therapeutics, University of
50 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- 51 22. Institute of Translational Medicine and Therapeutics, University of Pennsylvania Perelman
52 School of Medicine, Philadelphia, PA, USA.
- 53 23. Veterans Affairs Providence Healthcare System, Providence, RI, USA.
- 54 24. Brown University, Providence, RI, USA.
- 55 25. VA Atlanta Health Care System, Decatur, GA, USA.
- 56 26. Emory University Rollins School of Public Health, Atlanta, GA, USA.
- 57 27. Department of Epidemiology and Public Health, Graduate School of Medical Sciences,
58 Kyushu University.
- 59 28. Department of Frontier Cardiovascular Science, Graduate School of Medicine, The
60 University of Tokyo, Tokyo, Japan.
- 61 29. International University of Health and Welfare.

62

63 Correspondence should be addressed to K.I. (kaoru.ito@riken.jp) and I.K. (komuro-
64 tky@umin.ac.jp)

65 **Abstract:**

66 To understand the genetic basis of heart failure (HF) in the Japanese population, we performed
67 genome-wide association studies (GWASs) comprising 16,251 all-cause HF cases, 4,254 HF
68 with reduced ejection fraction cases, 7,154 HF with preserved ejection fraction cases, and 11,122
69 non-ischemic HF cases among 213,828 individuals and identified five novel loci. A subsequent
70 cross-ancestry meta-analysis and multi-trait analysis of the GWAS data identified 19 novel loci
71 in total. Among these susceptibility loci, a common non-coding variant in *TTN* (rs1484116) was
72 associated with reduced cardiac function and worse long-term mortality. We leveraged the HF
73 meta-GWASs along with cardiac function-related GWASs to develop a polygenic risk score
74 (PRS) for HF. The PRS successfully identified early-onset HF and those with an increased risk
75 of long-term HF mortality. Our results shed light on the shared and distinct genetic basis of HF
76 between Japanese and European populations and improve the clinical value of HF genetics.

77 **Introduction**

78 Heart failure (HF) is increasing in prevalence and incidence¹. A previous genome-wide
79 association study (GWAS) of all-cause HF identified 47 risk loci². Considering that GWAS of
80 coronary artery disease (CAD) yielded 175 susceptibility loci³ and GWAS of atrial fibrillation
81 (AF) yielded 150 loci⁴, the number of loci for HF was lower than expected even when using
82 multi-trait analysis of GWAS (MTAG) that jointly analyzes GWAS summary statistics of
83 multiple related traits, boosting statistical power by leveraging information across traits. This is
84 partly because HF is a heterogeneous syndrome resulting from multiple etiologies. GWAS of HF
85 with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) was
86 performed to address this heterogeneity⁵. This study identified additional susceptibility loci that
87 had not been found in the all-cause HF GWAS. Given this fact, analysis of HF subtypes should
88 be useful to better understand the genetic architecture for HF. On the other hand, since the vast
89 majority of these HF-GWASs have been performed in European populations, the genetic
90 pathophysiology of HF in non-European populations is not well understood. Additionally, it is
91 difficult to apply polygenic risk scores (PRSs) derived from such GWASs to non-European
92 populations.

93 Therefore, in the present study, we performed a large-scale Japanese GWAS to explore
94 the genetic architecture of all-cause HF and HF subtypes: HFrEF, HFpEF, and non-ischemic HF
95 (NIHF), followed by a cross-ancestry meta-analysis. Further, we investigated potential causal
96 genes at the identified HF-associated loci by integrating several prioritization methods to
97 characterize the underlying mechanism, clarify the link with cardiomyopathy, and propose gene-
98 drug interactions relevant to HF. We also evaluated the impact of common variants in
99 established cardiomyopathy genes on HF phenotypes and long-term mortality. Subsequently, we

100 identified a *TTN* common variant, which affected HF severity and mortality rate. Additionally,
101 we developed a PRS derived from the cross-ancestry meta-analysis of each HF subtype along
102 with HF-related phenotypes and demonstrated the ability of the HF-PRS to predict the early
103 onset of HF and stratify the long-term mortality, which may provide evidence for the clinical
104 utility of HF-PRS and lay the foundation for the realization of precision medicine in HF.

105 **Results**

106 **GWAS revealed a Japanese-specific genetic architecture of HF**

107 An overview of the study design is shown in **Fig. 1**. We performed Japanese case-control
108 GWASs to investigate the association of up to 7,974,473 common genetic variants in the
109 autosomes (minor allele frequency (MAF) > 1%) with the risk of four HF phenotypes. 16,251
110 HF cases were identified, including 4,254 cases of HFrEF, 7,154 cases of HFpEF, and 11,122
111 cases of NIHF (**Fig. 1**). Cases of all-cause HF, HFrEF, and HFpEF were compared with 197,577
112 controls. For the NIHF analysis, CAD cases were excluded from control samples, and 171,995
113 controls were used. Sample overlaps between each HF phenotype are shown in **Supplementary**
114 **Fig. 1a**. The mean LV ejection fraction (LVEF) was 48.94% for all-cause HF, 28.74% for
115 HFrEF, 62.08% for HFpEF, and 50.86% for NIHF (**Supplementary Table 1**). These GWASs
116 identified 18 genome-wide significant loci in total, of which five were previously unreported
117 (**Fig. 2a, Supplementary Fig. 1b, Supplementary Fig. 1c, Supplementary Table 2, and**
118 **Supplementary Datasets**). The estimated heritability for each HF phenotype is described in
119 **Supplementary Notes 1**. We assessed the 62 previously reported HF loci and confirmed that
120 their effects were mostly concordant with our Japanese GWAS (**Supplementary Notes 2,**
121 **Supplementary Fig. 2, Supplementary Table 3**). Additionally, while the reproducibility of the
122 novel loci was obtained in both internal and external replications, two of the novel loci were
123 specific to the Japanese population and were not found in Europeans (**Supplementary Notes 3,**
124 **Supplementary Fig. 3a, b, c, d and Supplementary Table 4, 5**).

125 To identify HF-associated variants independent of the lead variant at each locus, we
126 performed a stepwise conditional analysis, in which three independent variants (locus-wide $P <$
127 5.0×10^{-6}) were additionally detected, increasing the total number of HF-associated signals to 21

128 **(Supplementary Table 6)**. Among these, the frequencies of rs893363 (Alternative allele
129 frequency; EAS 96.2% vs. EUR 61.9%, $\beta = -0.167$ in NIHF) and rs4307025 (Alternative allele
130 frequency; EAS 73.0% vs. EUR 28.0%, $\beta = 0.0912$ in NIHF) differed significantly between East
131 Asians and Europeans.

132 To assess the pleiotropic effects, we used the lead variant in each locus as a proxy and
133 assessed its effect sizes in Japanese GWAS of cardiovascular-related phenotypes⁶. The novel
134 variant rs35593046 found in all-cause HF ($\beta = -0.0630$) /NIHF ($\beta = -0.0767$) had a protective
135 role against high blood pressure (**Supplementary Fig. 4a** and **Supplementary Table 7**). It is the
136 intronic variant of *CACNAID* and is much more frequently observed in the East Asian
137 population than in European populations (53.8% vs. 26.8%).

138

139 **Common variants in cardiomyopathy genes were responsible for HF development**

140 We then sought to prioritize potential causal genes at the identified HF-associated loci.
141 First, of the 310 variants in LD ($r^2 > 0.8$) with 18 lead variants, 6 missense variants were
142 observed (**Supplementary Table 8**). Among loci previously reported only in the multi-trait
143 analysis of GWAS (MTAG), we found missense variants rs11718898, rs2305398, and rs3732678
144 in the *CAND2* gene, three of which were in high LD. *CAND2* has been reported to link mTOR
145 signaling to pathological cell growth leading to cardiac remodeling⁷. A missense variant
146 rs2627043 found in the HFrEF GWAS encodes *TTN*, one of the well-known cardiomyopathy
147 genes. Notably, the allele frequency was much higher in the East Asian population than in
148 European populations (64.7% vs. 20.1%). We also found the East Asian-specific missense
149 variant rs671 encoding *ALDH2*, which has been reported to be an HF-related variant in the BBJ
150 1st cohort⁶.

151 Next, we assessed whether the lead variants we identified were functioning as an
152 expression quantitative trait locus (eQTL) or a splicing quantitative trait locus (sQTL) using
153 GTEx version 8 data. Among the lead variants in novel loci, rs6471480 was found to be an
154 eQTL in subcutaneous adipose tissue (**Supplementary Fig. 4c** and **Supplementary Table 9**)
155 and an sQTL in the left atrial appendage (**Supplementary Fig. 4d** and **Supplementary Table**
156 **10**) for the *DPY19L4* gene. Additionally, all of the five HFrEF-related variants, previously
157 identified only in MTAG with cardiac measurements², were revealed as eQTL in the left
158 ventricle. This result may suggest that MTAG in the previous study conferred additional
159 statistical power to discover these variants by integrating cardiac function-related traits.

160 We conducted gene-based analyses, MAGMA⁸ and H-MAGMA⁹, utilizing promoter
161 capture Hi-C in cardiovascular-related tissues¹⁰. Among novel loci, *DPY19L4* reached statistical
162 significance (FDR < 0.05) in the aorta and adrenal gland using H-MAGMA but not MAGMA
163 (**Supplementary Fig. 4e** and **Supplementary Table 11-12**). Given that the aorta and adrenal
164 gland are known to be involved in the pathophysiology of hypertension, this is consistent with
165 the association of *DPY19L4* with the use of a calcium channel blocker, one of the
166 antihypertensive drugs⁶.

167 Furthermore, related to the HF loci identified in our Japanese GWAS, we assessed nearby
168 genes containing variants classified in ClinVar as having pathogenic evidence for HF-relevant
169 monogenic disorders, knock-out mouse phenotype, and known cardiomyopathy genes¹¹. *NEBL*,
170 located within 500kb of the lead variant rs7075837, was reported to harbor pathogenic variants
171 responsible for primary dilated cardiomyopathy according to the ClinVar database
172 (**Supplementary Table 13**). *NEBL* was also one of the known cardiomyopathy genes
173 (**Supplementary Table 14**), and *Nebl* knock-out mice showed dilatation of the left atrium and

174 ventricle (**Supplementary Table 15**). *SPRED2* harbors pathogenic variants responsible for
175 Noonan syndrome, which causes hypertrophic cardiomyopathy (**Supplementary Table 13**).
176 Knock-out of *Spred2* also causes dilatation of the heart (**Supplementary Table 15**). Knock-out
177 of *Csmd1* showed obesity and abnormal glucose metabolism (**Supplementary Table 15**).
178 Polygenic Priority Score (PoPS) was recently introduced to estimate responsible genes using
179 various gene features, such as cell-type-specific gene expression and biological pathways. We
180 thus used PoPS to choose the top two likely genes in each locus. As a result, *SPRED2* and
181 *CSMD1* were also prioritized (**Supplementary Table 16**).

182 Taken together, *DPY19LA*, *CSMD1*, *SPRED2*, and *NEBL* were prioritized by at least
183 three out of 10 predictors as Japanese-specific HF-related genes (**Fig. 2a, 2b**, and
184 **Supplementary Table 17**). Of note, common variants in cardiomyopathy genes *NEBL* were also
185 responsible for HF development. *NEBL* encodes the cardiac Z-disk protein nebulin, and rare
186 variants in this region cause dilated, hypertrophic, and LV non-compaction cardiomyopathy¹².
187 *DPY19LA* was likely to act on arteries to cause hypertension based on pleiotropic effects and H-
188 MAGMA results. This interpretation was supported by the fact that quercetin, which attenuated
189 atherosclerosis via modulating oxidized LDL-induced endothelial cellular senescence,
190 downregulated *DPY19LA* in human aortic endothelial cells¹³. Based on knockout phenotypes,
191 *CSMD1* is likely to cause HF through metabolic disorders, consistent with a previous study¹⁴.
192 *SPRED2* loss-of-function induced defects in convergence and extension cell movements leading
193 to cardiac defects and Noonan-like syndrome¹⁵. Aside from novel loci, *AOPEP*, previously
194 reported in Japanese all-cause HF GWAS⁶, was also associated with HFrEF, HFpEF, and NIHF
195 and the Japanese-specific signal (**Supplementary Fig. 5**). Given that *AOPEP* cleaves

196 angiotensin III to angiotensin IV, a bioactive peptide of the renin-angiotensin pathway, it is
197 likely that *AOPEP* is responsible for HF development through hypertension.

198

199 **Cross-ancestry meta-analysis identified seven novel loci for HF**

200 To improve the statistical power to detect further genetic associations with HF, we
201 conducted cross-ancestry meta-analyses by combining the current Japanese GWAS (BBJ), along
202 with European², Chinese¹⁶, American¹⁷, and African² all-cause HF GWAS, European HF_{rEF} and
203 HF_{pEF} GWAS⁵, and the UK biobank¹⁸ and FinnGen (data release 9) NIHF GWAS
204 (**Supplementary Table 18** and **Supplementary Notes 4**). These analyses identified 58 HF-
205 associated loci with genome-wide significance ($P < 5.0 \times 10^{-8}$; **Supplementary Fig. 6**,
206 **Supplementary Fig. 7a**, **Supplementary Table 19**, and **Supplementary Datasets**). Of these
207 loci, seven have not been reported previously, including one novel locus detected in the current
208 Japanese GWAS (*CACNA1D* locus). In total, we identified 11 novel loci through the current
209 Japanese GWAS and cross-ancestry meta-analysis.

210 In internal replication, all the newly identified loci were nominally significant both in
211 East Asian and European populations (**Supplementary Fig. 7b** and **Supplementary Table 20**).
212 rs35593046 (*CACNA1D*), rs7659823 (*EDNRA*), rs5823966 (*ZNF397*), and rs1541596 (*CARMI1*)
213 were much more frequently observed in the East Asian population (**Supplementary Fig. 7c** and
214 **Supplementary Table 20**). Replication analyses of three lead variants in HF_{rEF} and HF_{pEF}
215 using independent datasets showed concordant results with the same effect direction
216 (**Supplementary Notes 5**, **Supplementary Figure 7d, e**, and **Supplementary Table 21**).

217

218 **Genes related to arrhythmia, metabolism, and heart morphology were prioritized in the**
219 **cross-ancestry meta-analyses**

220 Of the 1,621 variants in LD ($r^2 > 0.8$) with 75 lead variants in any of the HF subtypes, 10
221 missense variants and one stop-gain variant were observed (**Supplementary Table 22**). We
222 found an additional missense variant rs2305397 in the *CAND2* gene.

223 We performed a transcriptome-wide association study (TWAS) and splicing-TWAS
224 using the identified loci in the cross-ancestry meta-analyses and the GTEx data. Among novel
225 loci, *ZNF397* was prioritized in the tibial artery by TWAS (**Supplementary Fig. 8a** and
226 **Supplementary Table 23**). As for loci previously found only in MTAG, *MTSSI*, *PROM1*, and
227 *SPATA24* were prioritized in the left ventricle or left atrial appendage and *CCDC136* was
228 prioritized in the tibial artery. The splicing-TWAS showed that *ZNF397* (left ventricle) and
229 *EDNRA* (left ventricle and left atrial appendage) were prioritized among the novel loci
230 (**Supplementary Fig. 8b** and **Supplementary Table 24**). *TTN*, *SMARCB1*, *SPATA24*,
231 *EFCAB13*, *CCDC136*, *CAND2*, and *CARM1* were prioritized in the left ventricle or left atrial
232 appendage. Gene-based analysis by MAGMA showed that *CACNA1D*, *LHX3*, *EDNRA*, and
233 *ZNF397* reached statistical significance (**Supplementary Fig. 8c** and **Supplementary Table**
234 **S25** and **S26**).

235 Among the novel loci, no gene harbored pathogenic variants responsible for
236 cardiovascular-related phenotypes according to the ClinVar database (**Supplementary Table**
237 **27**). Based on genetic knockout phenotypes in mice, *Cacna1d* deletion caused arrhythmia
238 (**Supplementary Table 28**) and was prioritized by PoPS (**Supplementary Table 29**). Knockout
239 of *Ednra* showed abnormal heart and aortic morphology (**Supplementary Table 28**) partly

240 because *Ednra* was associated with heart development¹⁹. Deletion of *Carm1* caused dilatation of
241 the left atrium, and deletion of *Lhx3* caused decreased body weight (**Supplementary Table 28**).

242 In the cross-ancestry meta-analyses, *EDNRA*, *ZNF397*, *CACNA1D*, *CARM1*, *LHX3*, and
243 *PDE3A* were prioritized by at least three predictors (**Fig. 2a, 2b**, and **Supplementary Table 30**).

244 Among these six genes, *EDNRA* and *PDE3A* were linked to existing medications (refer to
245 **Candidate drugs linked to disease susceptibility loci** section in the main text). No prioritized
246 gene was found associated with rs10851802 (**Supplementary Notes 6**).

247

248 **The HF-related common variant in the cardiomyopathy gene *MYBPC3* was identified in** 249 **MTAG**

250 To further enhance the statistical power of HF GWAS, we conducted MTAG²⁰. First, we
251 assessed the genetic correlation between HF and cardiac MRI parameters for the left ventricle¹¹,
252 left atrium²¹, right ventricle, right atrium²², left ventricular mass²³, and fibrosis²⁴. Because left
253 ventricular mass was strongly correlated with HF in all of the HF subtypes (**Supplementary Fig.**
254 **9a** and **Supplementary Table 31**), we integrated HF GWAS and left ventricular mass GWAS by
255 MTAG. We then found an additional eight novel loci (**Supplementary Fig. 9b, 9c**,
256 **Supplementary Table 32**, and **Supplementary Datasets**). Of the 1,597 variants in LD ($r^2 > 0.8$)
257 with 36 lead variants, seven missense variants were observed (**Supplementary Table 33**).

258 Among the novel loci, rs6265 is a missense variant for *BDNF* (**Supplementary Table 33**).

259 TWAS showed that *BDNF* and *ILRUN* were prioritized in the left ventricle and atrial appendage,
260 and *PLPP3* in the fibroblasts (**Supplementary Fig. 10a** and **Supplementary Table 34**).

261 Splicing-TWAS showed that *ILRUN* (left ventricle and atrial appendage), *BDNF* (coronary

262 artery/aorta/fibroblasts), and *SLC4A7* (fibroblasts) were prioritized (**Supplementary Figure 10b**

263 and **Supplementary Table 35**). *SLC4A7*, *MYBPC3*, *BDNF*, and *PCSK1* reached statistical
264 significance in gene-based analyses (**Supplementary Fig. 10c** and **Supplementary Table 36-**
265 **37**).

266 Combined with known Mendelian genes (**Supplementary Table 38**), mouse phenotypes
267 (**Supplementary Table 39**), and PoPS (**Supplementary Table 40**), *BDNF*, *MYBPC3*, *SLC4A7*,
268 *ILRUN*, *PCSK1*, *PTPRJ*, and *PLPP3* were prioritized (**Fig. 2a, 2b, Supplementary Table 41**).
269 Notably, common variants in one of the known cardiomyopathy genes *MYBPC3* were
270 responsible for HF development as well as *TTN*, *NEBL* and *BAG3*. Other prioritized genes are
271 described in **Supplementary Notes 7**.

272 Here, comparing the disease susceptibility loci detected by the Japanese GWAS,
273 European GWAS, cross-ancestry meta-analyses, and MTAG, we found that there were common
274 and different genetic effects between the East Asian and European populations. Among novel
275 loci found in BBJ-specific or cross-ancestry meta-analyses, *AOPEP*, *CSMD1*, *DPY19L4*, and
276 *SPRED2* were significant only in the East Asian population (**Supplementary Fig. 4** and
277 **Supplementary Fig. 11**). On the other hand, *HLA-B*, *APOH*, *CFL2*, *HSD17B12*, *UBA7* were
278 European specific loci (**Supplementary Fig. 11**).

279

280 **Distinct mechanism of each HF phenotype in cross-ancestry analysis**

281 To compare the mechanisms of each HF phenotype, we conducted a pathway analysis
282 and found that cellular senescence, cyclin-dependent kinase-related pathway, miRNAs involved
283 in DNA damage responses, signaling events mediated by prolactin, Tie2 mediated signaling, and
284 Notch signaling pathway were enriched in all-cause HF (**Fig. 3** and **Supplementary Table 42**).
285 Notch signaling was also enriched in NIHF. From a clinical perspective, miRNAs involved in

286 DNA damage response may be attractive targets to improve cancer patient outcomes in
287 chemotherapy-related cardiomyopathy, which may be induced by DNA-damaging
288 chemotherapy. The prolactin inhibitor bromocriptine had higher odds of left ventricular function
289 recovery in peripartum cardiomyopathy, one of the leading causes of maternal mortality²⁵. Tie2-
290 mediated signaling is not only required for normal vascular development but also is required for
291 ventricular chamber formation²⁶. Notch is associated with heart development and regulates
292 cardiac regenerative processes²⁷. Aside from cyclin-dependent kinase-related pathways,
293 sarcomere-related pathways including Z-disc, I-band, and actin-binding were enriched in HFrEF
294 (**Fig. 3** and **Supplementary Table 42**). Cardiac cell development/differentiation was enriched in
295 NIHF. On the other hand, no specific pathway was enriched in HFpEF.

296 Additionally, cell type-specific enrichment analysis with gene expression and epigenetic
297 marks showed that H3K4me1 in the fetal heart was enriched in HFrEF, but the other three HF
298 phenotypes did not show any particular cell type enrichment (**Supplementary Table 43**). Taken
299 together, despite the smaller sample size, HFrEF showed strong enrichment in the heart,
300 especially in the sarcomere.

301 With miRNA enrichment analysis using MIGWAS, HFrEF showed significant
302 enrichment for the miRNA-target gene network (**Supplementary Figure 12a**). Out of eight
303 candidate miRNA-gene pairs (**Supplementary Table 44**), HSPB7 was also significant in TWAS
304 analysis (**Supplementary Table 34**), suggesting that hsa-mir-4728-*HSPB7* was the most likely
305 pair. *HSPB7* has been reported to be indispensable for heart development and associated with
306 dilated cardiomyopathy⁴⁷.

307 We conducted the cell type-specific analysis at single-cell resolution using scDRS⁴⁸ with
308 healthy, dilated cardiomyopathy, and hypertrophic cardiomyopathy datasets⁴⁹. All four HF

309 phenotypes showed significant enrichment for cardiomyocytes (**Supplementary Fig 12b** and
310 **Supplementary Table 45**). Additionally, HFpEF showed enrichment for adipocyte and vascular
311 smooth muscle cells^{50,51}, suggesting that HFpEF may have additional mechanisms beyond the
312 other HF phenotypes.

313

314 **Candidate drugs linked to disease susceptibility loci**

315 We curated drugs from DrugBank²⁸ and Therapeutic Target Database^{29,30}
316 (**Supplementary Fig. 13**) for the prioritized genes from the Japanese GWAS, cross-ancestry
317 meta-analyses, and MTAG. Our analysis supports epidemiological evidence that several
318 medications cause or exacerbate HF. Given that knockout of *CACNA1D*, *EDNRA*, and *CDK6* in
319 mice caused abnormal myocardial fiber physiology, abnormal heart ventricle morphology, and
320 decreased myocardial fiber number, respectively, those inhibitors could worsen HF. Indeed, the
321 previous meta-analysis suggested that dihydropyridine calcium channel blockers (nifedipine) can
322 be a risk for HF³¹. The EDNRA inhibitor bosentan caused fluid retention in HF patients³². One of
323 the CDK4/6 inhibitors, palbociclib, was associated with worse outcomes in patients who
324 developed atrial fibrillation or HF³³. All these outcomes were concordant with our genetic
325 analyses.

326 Tirzepatide, one of the emerging antidiabetics^{34,35}, could be a potential drug
327 repositioning candidate through the *GIPR* locus, which had a protective role against HF. As of
328 now, tirzepatide has not been fully evaluated for its effects on cardiovascular outcomes, but at
329 least it did not increase the risk of cardiovascular events³⁶. Currently, a study of tirzepatide in
330 participants with HFpEF (SUMMIT trial) is ongoing (NCT04847557).

331

332 **A *TTN* common variant plays an important role in HF outcomes**

333 From the Japanese GWAS and cross-ancestry meta-analyses, we found lead variants
334 associated with cardiomyopathy genes, *TTN*, *NEBL*, and *BAG3* (**Supplementary Table 14**).
335 Given the nature of cardiomyopathy genes, we hypothesized that these variants by themselves
336 could affect cardiac function and prognosis. Among those, the risk allele of *TTN* lead variant
337 (rs1484116) was less frequent in the East Asian populations than in European populations (Risk
338 allele frequency: EUR 0.800, EAS 0.315; **Fig. 4a**) according to the gnomAD database, while we
339 observed the effect size of this variant was higher in Japanese than Europeans (**Fig. 4b**). First, we
340 investigated the association between these variants and cardiac function, and we found that the
341 lead variants of *TTN* (rs1484116) and *BAG3* (rs61870083) were significantly associated with
342 lower left ventricular ejection fraction (*TTN*, effect size -1.16, 95% confidence interval (95%CI)
343 -1.55 - -0.77, $P = 7.80 \times 10^{-9}$; *BAG3*, effect size -2.79, 95%CI -3.58 - -2.00, $P = 3.88 \times 10^{-12}$;
344 **Fig. 4c**). We then repeated the same analysis in NIHF to exclude possible effects of CAD, and it
345 yielded similar results (**Fig. 4c**). These variants of *TTN* and *BAG3* were also associated with
346 lower LVEF in individuals without known cardiac diseases in UKBB cohorts (**Fig. 4c** right
347 panel). Furthermore, we assessed the effects of these common variants on long-term HF
348 mortality among non-HF subjects and HF subjects. The Kaplan-Meier estimates and Cox
349 regression analysis demonstrated that the *TTN* lead variant (rs1484116) was significantly
350 associated with worse outcomes in HF patients (HR 1.24, 95%CI 1.06-1.46, $P = 8.12 \times 10^{-3}$; **Fig.**
351 **4d** and **e**). These results suggest the importance of the *TTN* common variant in risk stratification
352 of HF patients and this variant could be a novel potential biomarker for HF.

353

354 **Development of a HF-PRS and its performance**

355 Although most GWASs have been conducted in European populations, PRSs derived
356 from European GWASs have shown poorer performance in other populations. On the other hand,
357 PRSs derived from cross-ancestry GWASs have been reported to improve their accuracy in
358 understudied populations³. Furthermore, integrating not only cross-ancestry GWAS of interest
359 but also related phenotypes (e.g., blood pressure and LDL cholesterol for CAD) has proved to
360 enhance the PRS performance³⁷. Here, we split our case-control samples into the derivation
361 dataset, dataset for linear combination, test dataset, and survival analysis dataset to avoid sample
362 overlap (**Supplementary Fig. 14**). We derived each PRS from the Japanese all-cause HF,
363 European/American/African all-cause HF, and European HFrEF, HFpEF, CAD, AF, and left
364 ventricular mass with PRS-CS (see Methods section). The linear combination of these PRS was
365 performed by Lasso regression with 10-fold cross-validation, resulting in the exclusion of PRSs
366 calculated from Native American all-cause HF, and European NIHF. For the PRS derived from a
367 single population GWAS, as concordant with the population specificity, the PRS derived from
368 BBJ showed higher performance in the Japanese population than those from European (pseudo
369 $R^2 = 0.709$ in European versus 0.737 in BBJ; **Fig. 5a**) despite the smaller sample size. As
370 suggested previously, cross-ancestry PRS showed higher performance than those from single
371 population-derived PRS (**Fig. 5a** and **Supplementary Fig. 15a**). Additionally, combining HF-
372 related phenotypes further improved the performance (**Fig. 5a** and **Supplementary Fig. 15a**).
373 Hereafter, we used the best model (model J in **Fig. 5a**). The risk of developing HF in individuals
374 with top PRS quintile was two times higher than that with bottom quintile (pseudo R^2 with 95%
375 CI for bottom quintile, 0.095 [0.084-0.107]; top quintile, 0.198 [0.183-0.214]; **Supplementary**
376 **Fig. 15b**).

377

378 **Impact of HF-PRS on HF phenotypes and outcomes**

379 The impact of HF-PRS on long-term outcomes has not been previously evaluated. Earlier
380 all-cause HF GWAS² and HF_{rEF}/HF_{pEF} GWAS⁵ did not develop a PRS. Although the Global
381 Biobank Meta-analysis Initiative (GBMI) developed an HF-PRS, it only assessed the predictive
382 performance and not the clinical impact³⁸. To assess the potential of the HF-PRS for clinical
383 applications, we investigated the association between the PRS and the onset age of HF in
384 individuals from our BBJ case samples (n =10,810). We observed that the onset age decreased as
385 the PRS increased; individuals with the top tertile PRS were estimated to be approximately two
386 years younger at HF onset compared to the bottom tertile individuals (**Fig. 5b**). To further
387 explore the clinical utility of the HF-PRS, we assessed its impact on mortality using long-term
388 follow-up data in BBJ. We stratified individuals without HF by tertiles (low, intermediate, and
389 high groups) based on their PRS scores. The Kaplan–Meier estimates of cumulative
390 cardiovascular mortality rate were significantly increased in the high PRS group. Furthermore,
391 we demonstrated that the HF-PRS successfully stratified the risk of HF death (**Fig. 5c**).

392 **Discussion**

393 We performed a large-scale GWAS with 16,251 HF cases and subtypes in the Japanese
394 population along with cross-ancestry meta-GWAS and MTAG boosted by heart function-related
395 traits and identified 19 novel loci. Additionally, through various gene prioritization approaches,
396 we elucidated associations with clinical risk factors, cardiomyopathy, and drug targets.
397 Furthermore, analysis of various datatypes in the biobank, including clinical and long-term
398 prognosis data from biobanks, confirmed the identification of significant HF variants and the
399 clinical utility of HF-PRS described here.

400 The Japanese GWAS identified 20 genome-wide significant loci associated with HF. This
401 includes five new loci, where variants significantly prevalent in East Asians. We identified a
402 novel association in the *CACNAID* loci, suggesting the involvement of functional alterations in
403 the calcium voltage-gated channel as a mechanism underlying HF. Since *CACNAID* encodes the
404 pore-forming $\alpha 1$ subunit of $Ca_v1.3$ voltage-gated L-type calcium channels (LTCC) and is highly
405 expressed in the sinus node and atrioventricular nodes³⁹. Mutations in *CACNAID* have been
406 proved to cause sinoatrial node dysfunction⁴⁰ suggesting the contribution of *CACNAID* in the
407 development of HF through chronotropic incompetence.

408 Furthermore, we performed cross-ancestry meta-analyses for HF subtypes, where 58
409 genome-wide significant loci were identified, resulting in the discovery of eight new loci.
410 Among the prioritized genes based on the GWAS, *EDNRA*, and *CACNAID* had a protective role
411 against heart failure and are drug targets for other diseases. Both *EDNRA* inhibitors and
412 *CACNAID* inhibitors have already been reported to exacerbate HF, an observation that was
413 successfully supported by our genetic analysis. We also identified a GIP/GLP-1-agonist as a drug

414 repositioning candidate. By contrast, we genetically proved the detrimental effects of PDE3A
415 and CDK4/6 blockade on HF pathogenesis.

416 In these analyses, we found that common variants of the cardiomyopathy genes *TTN*,
417 *NEBL*, and *BAG3* contributed to the development of HF. MTAG additionally identified that
418 common variants of *MYBPC3* were one of the susceptibility loci. Among these, a *TTN* common
419 variant rs1484116 had a significant difference in the frequency and effect between Japanese and
420 European populations. Notably, this common variant stratified individuals who went on to
421 develop HF into those with a high mortality rate. Additionally, while rare truncating variants in
422 the *TTN* gene comprise the most common genetic subtype of dilated cardiomyopathy, accounting
423 for up to 25% of cases⁴¹, we show for the first time that the *TTN* common variant in a non-coding
424 region also causes HF.

425 Integrating cross-ancestry GWAS of interest and GWAS of related phenotypes improves
426 predictive performance in CAD³⁷. In our HF-PRS, integrating HFrEF, HFpEF, AF, CAD, and
427 left ventricular mass improved the performance. Moreover, we demonstrated that HF-PRS could
428 predict HF death in subjects who had not yet been diagnosed as having HF.

429 Our study has several limitations. First, we did not have other large cohorts for the
430 replication analysis. We did not replicate Japanese-specific HF loci using other East Asian
431 cohorts since there were no other large East Asian biobanks available with enough of these
432 patients. Instead, we assessed these variants with European data, showing the same effect
433 direction. As for cross-ancestry meta-analyses, we did not have a non-overlapping corresponding
434 cohort for all-cause HF and NIHF. Hence, we used European all-cause HF data for the
435 replication of HFrEF and HFpEF cross-ancestry meta-analyses, showing almost the same effect
436 direction. Second, we did not perform quantitative trait-based enrichment analysis (e.g. TWAS

437 and splicing-TWAS) for the Japanese GWAS since there is no available molecular QTL dataset
438 for the East Asian population. Thus, eQTL, sQTL, and other QTL datasets of the East Asian
439 population are required in future research to further clarify the genetic differences between the
440 East Asian and European populations.

441 In conclusion, our large-scale Japanese and cross-ancestry genetic analyses identified 19
442 new risk loci and provided insights into the distinct and shared genetic architecture of HF
443 between Japanese and Europeans. Multiple prioritization methods allowed us to identify
444 candidate genes involved in the pathogenesis. We also showed that the common variant of *TTN*
445 can be a prognostic marker for HF patients in the Japanese population. Furthermore, analyses of
446 disease prediction and long-term survival demonstrated the clinical utility of our HF-PRS. These
447 data highlight the utility of HF genetics in clinical settings and provide useful evidence for the
448 implementation of genomic medicine.

449

450 **Online Methods**

451 **Study populations**

452 We included two cohorts for the Japanese-specific meta-analysis including the BBJ 1st
453 cohort and BBJ 2nd cohort from the BioBank Japan Project⁴². Further details on each cohort are
454 described in the **Supplementary Note**.

455 For GWAS quality control, we excluded samples with a call rate < 0.98 and related
456 individuals with $\pi\text{-hat} > 0.2$, which is an index of relatedness based on pairwise identity-by
457 descent implemented in PLINK 2.0 (20 Aug 2018 ver.). We then excluded samples with a
458 heterozygosity rate $> +4$ s.d. We performed principal component analysis (PCA) using PLINK
459 2.0. and excluded outliers from the Japanese cluster. For the case samples in GWAS, we selected
460 individuals with HF diagnosed by a physician based on accepted medical practice criteria.
461 HF_{rEF} was defined as having HF and LVEF $< 40\%$, while HF_{pEF} was defined as having HF
462 and LVEF $> 50\%$. NIHF was defined as having HF without CAD. The demographic features of
463 the case-control cohort are shown in **Supplementary Table 1**.

464

465 **Genotyping, imputation, and quality control**

466 To construct a population-specific reference panel, we included 7,825 Japanese WGS
467 samples. Each sample was aligned to the human genome assembly GRCh38 and subjected to
468 variant calling individually using the Illumina DRAGEN Bio-IT Platform (versions 3.4.12 and
469 3.5.7), generating gVCF files. Joint variant calling was subsequently performed with DRAGEN
470 (version 3.6.3), employing default parameters and filtering criteria. Next variant quality control
471 (QC) was conducted and variants from the jointly-called dataset were filtered out based on
472 several exclusion criteria: 1) the presence of multi-alleles; 2) singleton; 3) missing data rate $>$

473 5%; 4) Hardy-Weinberg Equilibrium (HWE) p -value $< 1 \times 10^{-6}$. After QC, VCF files were phased
474 on a whole-chromosome basis using SHAPEIT4 (version 4.2)⁴³.

475 GWAS subjects were genotyped using the Illumina Human OmniExpress Genotyping
476 BeadChip or a combination of Illumina HumanOmniExpress and HumanExome BeadChips
477 (Illumina, San Diego, CA). For genotype quality control (QC), we excluded variants with (i)
478 SNP call rate < 0.99 , (ii) MAF < 0.01 , and (iii) Hardy-Weinberg equilibrium P value $< 1.0 \times$
479 10^{-6} . BBJ 1st and BBJ 2nd cohorts were separately phased using SHAPEIT2 (version r837) and
480 EAGLE2 (version 2.39), respectively. Imputation was then carried out with Minimac4 (version
481 1.0.0)⁴⁴ with a minor adjustment: variant positions in the array data, initially based on hg19, were
482 remapped to GRCh38 using BLAST based on the sequence of flanking sites.

483

484 **GWAS**

485 In the Japanese GWAS, association was performed by logistic regression analysis
486 assuming an additive model with adjustment for age, age², sex, and top 10 principal components
487 (PCs) using REGENIE⁴⁵. We selected variants with Minimac4 imputation quality score of > 0.3
488 and MAF ≥ 0.01 . The genome-wide significance threshold was defined at $P < 5.0 \times 10^{-8}$. The
489 genomic inflation factor (λ_{GC}) was 1.044, 1.080, 1.050, and 1.083 for all-cause HF, HF_rEF,
490 HF_pEF, and NIHF, respectively. (**Supplementary Figure. 2a**). Adjacent genome-wide
491 significant SNPs were grouped into one locus if they were within 1 Mb of each other. We
492 defined a locus as follows: (1) extracted genome-wide significant variants ($P < 5.0 \times 10^{-8}$) from
493 the association result, (2) added 500 kb to both sides of these variants, and (3) merged
494 overlapping regions. If the locus did not contain coordinates with previously reported genome-
495 wide significant variants (i.e., all variants with $P < 5.0 \times 10^{-8}$ in the previously reported locus),

496 the region was annotated as being novel. To identify independent association signals in the loci,
497 we conducted a stepwise conditional analysis for genome-wide significant loci defined as
498 described in the GWAS. First, we performed logistic regression conditioning on the lead variants
499 of each locus. We set a locus-wide significance at $P < 5.0 \times 10^{-6}$ and repeated this procedure
500 until none of the variants reached locus-wide significance for each locus.

501

502 **Linkage-disequilibrium score regression and heritability**

503 To estimate confounding biases such as cryptic relatedness and population stratification,
504 we performed a linkage-disequilibrium score regression (LDSC) (Version 1.0.0). We selected
505 SNPs with $MAF \geq 0.01$ and variants within the major histocompatibility complex region were
506 excluded. For the regression, we used the East Asian LD scores provided by the authors
507 (<https://github.com/bulik/ldsc/>). The all-cause HF population prevalence was set at 6.5%
508 according to the Japan Medical Data Center and the Medical Data Vision datasets⁴⁶. Since
509 37.4%, 45.1%, and 26.6% of all-cause HF were HFrEF, HFpEF, and NIHF, we assumed
510 population prevalence was 2.4% for HFrEF, 2.9% for HFpEF, and 1.7% for NIHF⁴⁷.

511

512 **Cross-ancestry meta-analysis**

513 All genomic coordinates were converted to GRCh37 with the liftover tool. Fixed-effect
514 meta-analyses based on inverse-variance weighting were performed for all HF phenotypes. We
515 defined genome-wide significant loci by iteratively spanning the ± 500 kb region around the most
516 significant variant and merging overlapping regions until no genome-wide significant variants
517 were detected within ± 1 Mb. A locus was categorized as “known” if the region after merging
518 was within ± 500 kb of variants for the corresponding phenotype in previous all-cause HF,

519 HFrEF, HFpEF, NIHF GWAS, “previously reported only in MTAG” if in previous all-cause HF
520 MTAG results², otherwise, it was categorized as a novel. The most significant variant in each
521 locus was selected as the index variant. Cochran’s Q-test for heterogeneity was conducted to
522 identify loci with index variants that have different effect sizes across GWAS data sets. We
523 filtered variants with strong heterogeneity ($P_{het} < 1.0 \times 10^{-4}$) or MAF < 1%.

524

525 **Multi-trait association study**

526 To identify additional HF-risk loci, we used MTAG²⁰ in Europeans, including cardiac
527 MRI traits, which were most strongly correlated with HF. We included left ventricular mass as it
528 was most strongly correlated with all HF phenotypes (**Supplementary Figure 9a**). We filtered
529 variants with MAF < 1% and defined genome-wide significant loci in the same way as trans-
530 ancestry meta-analysis.

531

532 **Independent follow-up of GWAS signals**

533 We sought to replicate internally the HF-risk loci reaching genome-wide significance in
534 the Japanese GWAS meta-analyses within BBJ1 and BBJ2. As for genome-wide significant
535 variants identified in the cross-ancestry meta-analysis, we assessed EUR and EAS. As external
536 replication of associations, we assessed significant variants identified in HFrEF or HFpEF using
537 European all-cause HF.

538

539 **Genetic correlation of HF and cardiac imaging traits**

540 Cross-trait LDSC was performed to estimate genetic correlation (r_g) between HF and
541 cardiac MRI traits. LDSC is a computationally efficient method that utilizes GWAS summary

542 statistics to estimate heritability and genetic correlation between polygenic traits while
543 accounting for sample overlap.

544

545 **Transcriptome-wide association study**

546 We performed a transcriptome-wide association study (TWAS) to assess gene-HF
547 associations using FUSION⁴⁸, which estimates the association between predicted gene
548 expression levels and a phenotype of interest using summary statistics and gene expression
549 prediction models. We used precomputed prediction models of gene expression in tissues
550 considered to be relevant for HF with LD reference data in GTEx v8 and the summary statistics
551 of the trans-ancestry HF-GWAS as input. Furthermore, we used the cross-tissue weights
552 generated in GTEx v8 using sparse canonical correlation analysis (sCCA) across 49 tissues
553 available on the FUSION website, including gene expression models for the first three canonical
554 vectors (sCCA1-3), which were shown to capture most of the gene expression signal.
555 Transcriptome-wide significant genes (eGenes) and the corresponding eQTLs were determined
556 using the Bonferroni correction, based on the average number of features (8,036.5 genes) tested
557 across all reference panels and correcting for the four HF phenotypes ($P < 1.55 \times 10^{-6}$). To
558 ensure that the observed associations did not reflect a random correlation between gene
559 expression and non-causal variants associated with stroke, we performed a colocalization
560 analysis on the eGenes to estimate the posterior probability of a shared causal variant between
561 the gene expression and trait association (PP4). eGenes presenting a $PP4 \geq 0.75$ were considered
562 to be significant.

563

564 **Splicing-TWAS**

565 We performed a splicing-TWAS to assess splicing-HF associations using MetaXcan. We
566 used GTEx v8 MASHR-based models (<https://github.com/hakyimlab/MetaXcan>). The
567 significant splicing sites were determined using the Bonferroni correction, based on the number
568 of splicing sites multiplied by the four HF phenotypes.

569

570 **Identifying protein-altering variants**

571 To identify protein-altering variants among our genome-wide significant associations, we
572 took the sentinel variants and their LD proxies at $r^2 \geq 0.8$ as estimated in the European ancestry
573 subset of 1000 Genomes Project phase 3 and annotated them using the Ensembl VEP. We
574 selected for each sentinel variant any proxies identified as having a ‘high’ (that is, stop-gain and
575 stop-loss, frameshift insertion and deletion, donor and acceptor splice-site and initiator codon
576 variants) or ‘moderate’ (that is, missense, in-frame insertion and deletion, splice region)
577 consequence and recorded the gene that the variant disrupts.

578

579 **Polygenic prioritization of candidate causal genes**

580 We implemented PoPS, a similarity-based gene prioritization method designed to
581 leverage the full genome-wide signal to nominate causal genes independent of methods utilizing
582 GWAS data proximal to the gene (<https://github.com/FinucaneLab/pops.git>). Broadly, PoPS
583 leverages polygenic enrichments of gene features including cell-type-specific gene expression,
584 curated biological pathways, and protein-protein interaction networks to train a linear model to
585 compute a PoPS for each gene.

586

587 **Variants responsible for cardiovascular-relevant monogenic disorders**

588 To identify genes harboring pathogenic variants responsible for HF-relevant monogenic
589 disorders, we searched the NCBI's ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>).
590 Variants were pruned to those within ± 500 kb of our HF sentinel variants; categorized as
591 'pathogenic' or 'likely pathogenic'; with a listed phenotype; and with either (i) details of the
592 evidence for pathogenicity, (ii) expert review of the gene or (iii) a gene that appears in practice
593 guidelines⁴⁹. We then filtered the variants that were annotated with a manually curated set of
594 cardiovascular-relevant phenotype terms, including those related to HF and HF risk factors
595 (**Supplementary Tables 12, 24, and 35**). Where a variant was annotated with multiple genes,
596 both genes were considered as potentially pathogenic.

597

598 **Phenotyping knock-out mice**

599 Human gene symbols were mapped to gene identifiers (HGNC) and mouse ortholog
600 genes were obtained using Ensembl (www.ensembl.org). Phenotype data for single-gene knock-
601 out models were obtained from the International Mouse Phenotyping Consortium, data release
602 19.1 (www.mousephenotype.org), and from the Mouse Genome Informatics database, data from
603 July 2023 (www.informatics.jax.org). For each mouse model, reported phenotypes were grouped
604 using the mammalian phenotype ontology hierarchy into broad categories relevant to HF as
605 follows: abnormal glucose homeostasis (MP:0002078), abnormal blood coagulation
606 (MP:0002551), muscle phenotype (MP:0005369), abnormal lipoprotein level (MP:0010329),
607 abnormal catecholamine level (MP:0011479), abnormal myofibroblast differentiation
608 (MP:0012196), cardiac edema (MP:0012270), abnormal lipid metabolism (MP:0013245),
609 adipose tissue necrosis (MP:0013249), abnormal susceptibility to non-insulin-dependent diabetes
610 (MP:0020086), abnormal fibroblast physiology (MP:0020414), abnormal adipose tissue

611 noradrenaline turnover (MP:0021021), cardiac amyloidosis (MP:0021148) along with
612 phenotypes previously used in CAD analysis⁴⁹ (**Supplementary Table 46**). This resulted in
613 mapping from genes to phenotypes in animals (**Supplementary Tables 14, 25, and 36**).

614

615 **PRS derivation and performance**

616 First, we divided our dataset into three groups: (i) a discovery group to derive PRS
617 (12,335 cases and 107,333 controls), (ii) a group used for linear combination (1,837 cases and
618 11,320 controls), (iii) a test group to assess PRS performance (1,837 cases and 11,319 controls),
619 and (iv) a group for the survival analysis (67,991 controls) (**Supplementary Fig. 14**). Next, we
620 used PRS-CS to derive each PRS from Japanese-, European-, American-, African- all-cause HF,
621 European HFrEF, HFpEF, NIHF, AF, CAD, and left ventricular mass. We used LD reference
622 panels constructed using the 1000 Genomes Project phase 3 samples according to each cohort
623 population. Subsequently, we calculated PRSs in the withheld BBJ cohorts for linear
624 combination and conducted logistic regression with L1 regularization and 10-fold cross-
625 validation. Finally, we used the Japanese all-cause HF, European all-cause HF, European HFrEF,
626 European HFpEF, European CAD, European AF, and European left ventricular mass to construct
627 the HF-PRS. The performance of the PRS was measured as (1) Nagelkerke's pseudo- R^2 obtained
628 by modeling age, sex, the top 10 PCs, and normalized PRS and (2) the area under the curve of
629 the receiver operator curve in the same model as Nagelkerke's pseudo R^2 . Using the models
630 previously described, we calculated the PRSs and assessed their performance for the independent
631 test cohort.

632

633 **Association of HF-PRS with age of HF onset**

634 To assess the association between HF-PRS and age at HF onset, we extracted HF case
635 samples with available data on age at HF onset ($n = 10,810$, the median age of HF onset was 68
636 years of age [IQR 60–76]) and constructed a linear regression model of age at HF onset
637 including HF PRS along with sex and the top 10 PCs to estimate effects of HF-PRS on age of AF
638 onset.

639

640 **Survival analysis**

641 For survival analysis, the Cox proportional hazards model was used to assess the
642 association between HF-PRS and long-term mortality. We obtained survival follow-up data with
643 the ICD-10 code for 132,737 individuals from the BBJ dataset⁴². The causes of death were
644 classified into three categories according to ICD-10 codes: cardiovascular death (I00–I99) and
645 HF death (I50). For HF-PRS analysis, we used a holdout survival analysis cohort
646 (**Supplementary Figure 10**). The median follow-up period was 8.4 years (IQR 6.8 – 9.9). The
647 Cox proportional hazards model was adjusted for sex, age, the top 10 PCs, and disease status.
648 Analyses were performed with the R package survival v.2.44, and survival curves were estimated
649 using the R package survminer v.0.4.6, with modifications.

650

651 **Data availability**

652 Summary statistics of Japanese GWAS and polygenic risk scores derived in this study
653 will be publicly available at the National Bioscience Database Center
654 (<https://humandbs.dbcls.jp/en/>). The GWAS summary statistics for HF (GBMI American:
655 <https://www.globalbiobankmeta.org/>; Kadoorie: <https://www.ckbiobank.org/>; FinnGen NIHF:
656 [https://console.cloud.google.com/storage/browser/_details/finngen-public-data-](https://console.cloud.google.com/storage/browser/_details/finngen-public-data-r9/summary_stats/)
657 [r9/summary_stats/](https://console.cloud.google.com/storage/browser/_details/finngen-public-data-r9/summary_stats/), R9_I9_NONISCHCARDMYOP; UKBB NIHF: <https://cvd.hugeamp.org/>),
658 and cardiac MRI (left ventricle, right ventricle and atrium: <http://kp4cd.org/datasets/mi>; left
659 atrium: <https://zenodo.org/records/5074929>; left ventricular mass: <https://cvd.hugeamp.org/>)
660 traits are publicly available.

661

662 **Code Availability**

663 The code used in this study is available on reasonable request to the corresponding authors.

664

665 **Acknowledgements**

666 We thank the staff of BBJ for their assistance in collecting samples and clinical
667 information. We thank Naoko Miyagawa, Akio Wada, and Shuji Ito for their technical
668 assistance. This research was funded by the Japan Agency for Medical Research and
669 Development (AMED) (JP24bm1423005 to K.I, nos. JP24ek0210164, JP24tm0524004, and
670 JP24tm0624002 to K.I., S.N., and I.K., and nos. JP24km0405209 and JP20ek0109487 to K.
671 Miyazawa, K. I, S. K., S. N., H. Akazawa, and I. K.), Japan Foundation for Applied Enzymology
672 (to N.E), the Japan Society for the Promotion of Science (to N. E. and K. I.), and the Research
673 Funding for Longevity Sciences from NCGG (24–15 to K.O. and K.I.). BBJ was supported by

674 the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports,
675 Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002,
676 JP17km0305001, and JP24tm0624002.

677

678 **Author Contributions**

679 N. E., K. I., C. T., Y. K., T. N., and I. K. conceived and designed the study. K. I, C. T., K.
680 Matsuda., Y. M., and Y. K. collected and managed the BBJ sample. T. N, Y. M., and Y. K.
681 performed the genotyping. N. E, K. Miyazawa, S. K, H. I., R.K., H.Y., F.T., M.F., R.O.
682 performed the statistical analyses. N.E, K. I, C. T, S. K., K.T., X.L, K.O., Y. O., T.Y., Y. K.,
683 T.N., K.N., H. Akazawa, P.T.E., MG.L., SM.D., BF.V, J.J., and YV.S. contributed to data
684 collection, processing, analysis, and interpretation. K. I, C.T., Y K., H. Aburatani, P.T.E. and
685 I.K. supervised the study. N.E. and K.I. wrote the manuscript, and many authors have provided
686 valuable edits.

687

688 **Competing interests**

689 The authors declare no competing interests associated with this manuscript.

690

691 **References:**

- 692 1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H,
693 Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K and Filippatos G.
694 Heart failure: preventing disease and death worldwide. *ESC Heart Fail.* 2014;1:4-25.
- 695 2. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
696 Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
697 Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
698 Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
699 Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
700 Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
701 association and multi-trait analyses characterize the common genetic architecture of heart failure.
702 *Nat Commun.* 2022;13:6914.
- 703 3. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
704 H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
705 K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
706 Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
707 K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
708 specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci
709 for coronary artery disease. *Nat Genet.* 2020;52:1169-1177.
- 710 4. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki
711 H, Akiyama M, Koike Y, Kurosawa R, Yoshida H, Ozaki K, Onouchi Y, BioBank Japan P,
712 Takahashi A, Matsuda K, Murakami Y, Aburatani H, Kubo M, Momozawa Y, Terao C, Oki S,
713 Akazawa H, Kamatani Y and Komuro I. Cross-ancestry genome-wide analysis of atrial

- 714 fibrillation unveils disease biology and enables cardioembolic risk prediction. *Nat Genet.*
715 2023;55:187-197.
- 716 5. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
717 Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
718 Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved
719 versus reduced ejection fraction. *Nat Commun.* 2022;13:7753.
- 720 6. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshihara S, Narita A, Konuma
721 T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi
722 K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S,
723 Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y, FinnGen, Ito
724 K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo
725 M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K and
726 Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet.*
727 2021;53:1415-1424.
- 728 7. Gorska AA, Sandmann C, Riechert E, Hofmann C, Malovrh E, Varma E, Kmietczyk V,
729 Olschlager J, Jurgensen L, Kamuf-Schenk V, Stroh C, Furkel J, Konstandin MH, Sticht C,
730 Boileau E, Dieterich C, Frey N, Katus HA, Doroudgar S and Volkers M. Muscle-specific Cand2
731 is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling. *EMBO*
732 *Rep.* 2021;22:e52170.
- 733 8. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set
734 analysis of GWAS data. *PLoS Comput Biol.* 2015;11:e1004219.

- 735 9. Sey NYA, Hu B, Mah W, Fauni H, McAfee JC, Rajarajan P, Brennand KJ, Akbarian S
736 and Won H. A computational tool (H-MAGMA) for improved prediction of brain-disorder risk
737 genes by incorporating brain chromatin interaction profiles. *Nat Neurosci.* 2020;23:583-593.
- 738 10. Jung I, Schmitt A, Diao Y, Lee AJ, Liu T, Yang D, Tan C, Eom J, Chan M, Chee S,
739 Chiang Z, Kim C, Masliah E, Barr CL, Li B, Kuan S, Kim D and Ren B. A compendium of
740 promoter-centered long-range chromatin interactions in the human genome. *Nat Genet.*
741 2019;51:1442-1449.
- 742 11. Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, Guo X, Venkatesh BA,
743 Taylor KD, Post WS, Rich S, Lima JAC, Rotter JI, Philippakis A, Lubitz SA, Ellinor PT, Khera
744 AV, Kathiresan S and Aragam KG. Analysis of cardiac magnetic resonance imaging in 36,000
745 individuals yields genetic insights into dilated cardiomyopathy. *Nat Commun.* 2020;11:2254.
- 746 12. Perrot A, Tomasov P, Villard E, Faludi R, Melacini P, Lossie J, Lohmann N, Richard P,
747 De Bortoli M, Angelini A, Varga-Szemes A, Sperling SR, Simor T, Veselka J, Ozcelik C and
748 Charron P. Mutations in NEBL encoding the cardiac Z-disk protein nebullette are associated with
749 various cardiomyopathies. *Arch Med Sci.* 2016;12:263-78.
- 750 13. Jiang YH, Jiang LY, Wang YC, Ma DF and Li X. Quercetin Attenuates Atherosclerosis
751 via Modulating Oxidized LDL-Induced Endothelial Cellular Senescence. *Front Pharmacol.*
752 2020;11:512.
- 753 14. Nock NL, Wang X, Thompson CL, Song Y, Baechle D, Raska P, Stein CM and Gray-
754 McGuire C. Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart
755 Study using association and structural equation modeling methods. *BMC Proc.* 2009;3 Suppl
756 7:S50.

- 757 15. Motta M, Fasano G, Gredy S, Brinkmann J, Bonnard AA, Simsek-Kiper PO, Gulec EY,
758 Essaddam L, Utine GE, Guarnetti Prandi I, Venditti M, Pantaleoni F, Radio FC, Ciolfi A, Petrini
759 S, Consoli F, Vignal C, Hepbasli D, Ullrich M, de Boer E, Vissers L, Gritli S, Rossi C, De Luca
760 A, Ben Becher S, Gelb BD, Dallapiccola B, Lauri A, Chillemi G, Schuh K, Cave H, Zenker M
761 and Tartaglia M. SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype.
762 *Am J Hum Genet.* 2021;108:2112-2129.
- 763 16. Walters RG, Millwood IY, Lin K, Schmidt Valle D, McDonnell P, Hacker A, Avery D,
764 Edris A, Fry H, Cai N, Kretzschmar WW, Ansari MA, Lyons PA, Collins R, Donnelly P, Hill M,
765 Peto R, Shen H, Jin X, Nie C, Xu X, Guo Y, Yu C, Lv J, Clarke RJ, Li L, Chen Z and China
766 Kadoorie Biobank Collaborative G. Genotyping and population characteristics of the China
767 Kadoorie Biobank. *Cell Genom.* 2023;3:100361.
- 768 17. Zhou W, Kanai M, Wu KH, Rasheed H, Tsuo K, Hirbo JB, Wang Y, Bhattacharya A,
769 Zhao H, Namba S, Surakka I, Wolford BN, Lo Faro V, Lopera-Maya EA, Lall K, Fave MJ,
770 Partanen JJ, Chapman SB, Karjalainen J, Kurki M, Maasha M, Brumpton BM, Chavan S, Chen
771 TT, Daya M, Ding Y, Feng YA, Guare LA, Gignoux CR, Graham SE, Hornsby WE, Ingold N,
772 Ismail SI, Johnson R, Laisk T, Lin K, Lv J, Millwood IY, Moreno-Grau S, Nam K, Palta P,
773 Pandit A, Preuss MH, Saad C, Setia-Verma S, Thorsteinsdottir U, Uzunovic J, Verma A,
774 Zawistowski M, Zhong X, Afifi N, Al-Dabhani KM, Al Thani A, Bradford Y, Campbell A,
775 Crooks K, de Bock GH, Damrauer SM, Douville NJ, Finer S, Fritsche LG, Fthenou E, Gonzalez-
776 Arroyo G, Griffiths CJ, Guo Y, Hunt KA, Ioannidis A, Jansonius NM, Konuma T, Lee MTM,
777 Lopez-Pineda A, Matsuda Y, Marioni RE, Moatamed B, Nava-Aguilar MA, Numakura K, Patil
778 S, Rafaels N, Richmond A, Rojas-Munoz A, Shortt JA, Straub P, Tao R, Vanderwerff B,
779 Vernekar M, Veturi Y, Barnes KC, Boezen M, Chen Z, Chen CY, Cho J, Smith GD, Finucane

780 HK, Franke L, Gamazon ER, Ganna A, Gaunt TR, Ge T, Huang H, Huffman J, Katsanis N,
781 Koskela JT, Lajonchere C, Law MH, Li L, Lindgren CM, Loos RJJ, MacGregor S, Matsuda K,
782 Olsen CM, Porteous DJ, Shavit JA, Snieder H, Takano T, Trembath RC, Vonk JM, Whiteman
783 DC, Wicks SJ, Wijmenga C, Wright J, Zheng J, Zhou X, Awadalla P, Boehnke M, Bustamante
784 CD, Cox NJ, Fatumo S, Geschwind DH, Hayward C, Hveem K, Kenny EE, Lee S, Lin YF,
785 Mbarek H, Magi R, Martin HC, Medland SE, Okada Y, Palotie AV, Pasaniuc B, Rader DJ,
786 Ritchie MD, Sanna S, Smoller JW, Stefansson K, van Heel DA, Walters RG, Zollner S, Biobank
787 of the A, Biobank Japan P, BioMe, BioVu, CanPath - Ontario Health S, China Kadoorie Biobank
788 Collaborative G, Colorado Center for Personalized M, de CG, Estonian B, FinnGen, Generation
789 S, Genes, Health Research T, LifeLines, Mass General Brigham B, Michigan Genomics I,
790 National Biobank of K, Penn Medicine B, Qatar B, Sun QS, Health S, Taiwan B, Study H,
791 Initiative UACH, Uganda Genome R, Biobank UK, Martin AR, Willer CJ, Daly MJ and Neale
792 BM. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease.
793 *Cell Genom.* 2022;2:100192.

794 18. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
795 ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
796 G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
797 Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
798 Discovery. *Circulation.* 2019;139:489-501.

799 19. Asai R, Kurihara Y, Fujisawa K, Sato T, Kawamura Y, Kokubo H, Tonami K, Nishiyama
800 K, Uchijima Y, Miyagawa-Tomita S and Kurihara H. Endothelin receptor type A expression
801 defines a distinct cardiac subdomain within the heart field and is later implicated in chamber
802 myocardium formation. *Development.* 2010;137:3823-33.

- 803 20. Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, Nguyen-Viet TA,
804 Wedow R, Zacher M, Furlotte NA, andMe Research T, Social Science Genetic Association C,
805 Magnusson P, Oskarsson S, Johannesson M, Visscher PM, Laibson D, Cesarini D, Neale BM
806 and Benjamin DJ. Multi-trait analysis of genome-wide association summary statistics using
807 MTAG. *Nat Genet.* 2018;50:229-237.
- 808 21. Ahlberg G, Andreassen L, Ghouse J, Bertelsen L, Bundgaard H, Haunso S, Svendsen JH
809 and Olesen MS. Genome-wide association study identifies 18 novel loci associated with left
810 atrial volume and function. *Eur Heart J.* 2021;42:4523-4534.
- 811 22. Pirruccello JP, Di Achille P, Nauffal V, Nekoui M, Friedman SF, Klarqvist MDR,
812 Chaffin MD, Weng LC, Cunningham JW, Khurshid S, Roselli C, Lin H, Koyama S, Ito K,
813 Kamatani Y, Komuro I, BioBank Japan P, Jurgens SJ, Benjamin EJ, Batra P, Natarajan P, Ng K,
814 Hoffmann U, Lubitz SA, Ho JE, Lindsay ME, Philippakis AA and Ellinor PT. Genetic analysis
815 of right heart structure and function in 40,000 people. *Nat Genet.* 2022;54:792-803.
- 816 23. Khurshid S, Lazarte J, Pirruccello JP, Weng LC, Choi SH, Hall AW, Wang X, Friedman
817 SF, Nauffal V, Biddinger KJ, Aragam KG, Batra P, Ho JE, Philippakis AA, Ellinor PT and
818 Lubitz SA. Clinical and genetic associations of deep learning-derived cardiac magnetic
819 resonance-based left ventricular mass. *Nat Commun.* 2023;14:1558.
- 820 24. Nauffal V, Di Achille P, Klarqvist MDR, Cunningham JW, Hill MC, Pirruccello JP,
821 Weng LC, Morrill VN, Choi SH, Khurshid S, Friedman SF, Nekoui M, Roselli C, Ng K,
822 Philippakis AA, Batra P, Ellinor PT and Lubitz SA. Genetics of myocardial interstitial fibrosis in
823 the human heart and association with disease. *Nat Genet.* 2023;55:777-786.

- 824 25. Kumar A, Ravi R, Sivakumar RK, Chidambaram V, Majella MG, Sinha S, Adamo L,
825 Lau ES, Al'Aref SJ, Asnani A, Sharma G and Mehta JL. Prolactin Inhibition in Peripartum
826 Cardiomyopathy: Systematic Review and Meta-analysis. *Curr Probl Cardiol.* 2023;48:101461.
- 827 26. Qu X, Harmelink C and Baldwin HS. Tie2 regulates endocardial sprouting and
828 myocardial trabeculation. *JCI Insight.* 2019;5.
- 829 27. MacGrogan D, Munch J and de la Pompa JL. Notch and interacting signalling pathways
830 in cardiac development, disease, and regeneration. *Nat Rev Cardiol.* 2018;15:685-704.
- 831 28. Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin
832 NEL, Strawbridge SA, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R,
833 Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat DY, Jackson H, Harford K, Anjum A,
834 Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQR, Nguyen T, So D, Sharp M, da
835 Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V and
836 Wishart DS. DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res.*
837 2024;52:D1265-D1275.
- 838 29. Chen X, Ji ZL and Chen YZ. TTD: Therapeutic Target Database. *Nucleic Acids Res.*
839 2002;30:412-5.
- 840 30. Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y and Chen Y. Therapeutic target
841 database update 2022: facilitating drug discovery with enriched comparative data of targeted
842 agents. *Nucleic Acids Res.* 2022;50:D1398-D1407.
- 843 31. Chaugai S, Sherpa LY, Sepehry AA, Kerman SRJ and Arima H. Effects of Long- and
844 Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic
845 Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials. *J*
846 *Cardiovasc Pharmacol Ther.* 2018;23:433-445.

- 847 32. Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie
848 MC, DeMets D, Kobrin I, Roux S, Swedberg K, Investigators E and Committees. Long-Term
849 Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of
850 Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. *JACC*
851 *Heart Fail.* 2017;5:317-326.
- 852 33. Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S,
853 Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A and Gong Y. Adverse
854 Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With
855 Metastatic Breast Cancer. *J Am Heart Assoc.* 2023;12:e029361.
- 856 34. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK,
857 Liu B, Cui X, Brown K and Investigators S-. Tirzepatide versus Semaglutide Once Weekly in
858 Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385:503-515.
- 859 35. Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, Mao H, Cui
860 X, Karanikas CA and Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor
861 agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised,
862 phase 3 trial. *Lancet.* 2021;398:143-155.
- 863 36. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ and Zoungas S.
864 Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. *Nat Med.*
865 2022;28:591-598.
- 866 37. Patel AP, Wang M, Ruan Y, Koyama S, Clarke SL, Yang X, Tcheandjieu C, Agrawal S,
867 Fahed AC, Ellinor PT, Genes, Health Research T, the Million Veteran P, Tsao PS, Sun YV, Cho
868 K, Wilson PWF, Assimes TL, van Heel DA, Butterworth AS, Aragam KG, Natarajan P and

- 869 Khera AV. A multi-ancestry polygenic risk score improves risk prediction for coronary artery
870 disease. *Nat Med.* 2023;29:1793-1803.
- 871 38. Wang Y, Namba S, Lopera E, Kerminen S, Tsuo K, Lall K, Kanai M, Zhou W, Wu KH,
872 Fave MJ, Bhatta L, Awadalla P, Brumpton B, Deelen P, Hveem K, Lo Faro V, Magi R,
873 Murakami Y, Sanna S, Smoller JW, Uzunovic J, Wolford BN, Global Biobank Meta-analysis I,
874 Willer C, Gamazon ER, Cox NJ, Surakka I, Okada Y, Martin AR and Hirbo J. Global Biobank
875 analyses provide lessons for developing polygenic risk scores across diverse cohorts. *Cell*
876 *Genom.* 2023;3:100241.
- 877 39. Kanemaru K, Cranley J, Muraro D, Miranda AMA, Ho SY, Wilbrey-Clark A, Patrick
878 Pett J, Polanski K, Richardson L, Litvinukova M, Kumasaka N, Qin Y, Jablonska Z, Semprich
879 CI, Mach L, Dabrowska M, Richoz N, Bolt L, Mamanova L, Kapuge R, Barnett SN, Perera S,
880 Talavera-Lopez C, Mulas I, Mahbubani KT, Tuck L, Wang L, Huang MM, Prete M, Pritchard S,
881 Dark J, Saeb-Parsy K, Patel M, Clatworthy MR, Hubner N, Chowdhury RA, Nosedà M and
882 Teichmann SA. Spatially resolved multiomics of human cardiac niches. *Nature.* 2023;619:801-
883 810.
- 884 40. Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I,
885 Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P,
886 Striessnig J and Bolz HJ. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy
887 with bradycardia and congenital deafness. *Nat Neurosci.* 2011;14:77-84.
- 888 41. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L,
889 DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ,
890 Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE,


- 891 Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG and Seidman CE.
892 Truncations of titin causing dilated cardiomyopathy. *N Engl J Med*. 2012;366:619-28.
- 893 42. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T,
894 Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H,
895 Tanaka T, Ohnishi Y, Nakamura Y, BioBank Japan Cooperative Hospital G and Kubo M.
896 Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol*. 2017;27:S2-S8.
- 897 43. Delaneau O, Zagury JF, Robinson MR, Marchini JL and Dermitzakis ET. Accurate,
898 scalable and integrative haplotype estimation. *Nat Commun*. 2019;10:5436.
- 899 44. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy
900 S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A, Scott LJ, Cucca
901 F, Kronenberg F, Boehnke M, Abecasis GR and Fuchsberger C. Next-generation genotype
902 imputation service and methods. *Nat Genet*. 2016;48:1284-1287.
- 903 45. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C,
904 O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A, Reid J, Abecasis G,
905 Maxwell E and Marchini J. Computationally efficient whole-genome regression for quantitative
906 and binary traits. *Nat Genet*. 2021;53:1097-1103.
- 907 46. Zhang L, Ono Y, Qiao Q and Nagai T. Trends in heart failure prevalence in Japan 2014-
908 2019: a report from healthcare administration databases. *ESC Heart Fail*. 2023;10:1996-2009.
- 909 47. Ide T, Kaku H, Matsushima S, Tohyama T, Enzan N, Funakoshi K, Sumita Y, Nakai M,
910 Nishimura K, Miyamoto Y, Tsuchihashi-Makaya M, Hatano M, Komuro I, Tsutsui H and
911 Investigators J. Clinical Characteristics and Outcomes of Hospitalized Patients With Heart
912 Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure
913 (JROADHF). *Circ J*. 2021;85:1438-1450.

914 48. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, Jansen R, de Geus EJ,
915 Boomsma DI, Wright FA, Sullivan PF, Nikkola E, Alvarez M, Civelek M, Lusi AJ, Lehtimäki
916 T, Raitoharju E, Kahonen M, Seppälä I, Raitakari OT, Kuusisto J, Laakso M, Price AL,
917 Pajukanta P and Pasaniuc B. Integrative approaches for large-scale transcriptome-wide
918 association studies. *Nat Genet.* 2016;48:245-52.

919 49. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M,
920 Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM,
921 Sherliker P, Koyama S, Ishigaki K, Asvold BO, Brown MR, Brumpton B, de Vries PS,
922 Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Guldener U, Haider SMI, Helgadóttir A,
923 Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S,
924 Munz M, Murgia F, Nielsen JB, Nothen MM, Pang S, Reinberger T, Schnitzler G, Smedley D,
925 Thorleifsson G, von Scheidt M, Ulirsch JC, Biobank J, Epic CVD, Arnar DO, Burt NP,
926 Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta
927 LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdóttir U, Webb TR, Baras A, Björkegren
928 JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-
929 Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT,
930 Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J,
931 Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS and
932 Consortium CAD. Discovery and systematic characterization of risk variants and genes for
933 coronary artery disease in over a million participants. *Nat Genet.* 2022;54:1803-1815.

934
935

936 **Figures**



937

938 **Fig. 1 | Overview of the study design.** Flowchart of the study, which encompasses the Japanese

939 GWAS with the BioBank Japan, a trans-ancestry meta-analysis with large-scale European and


940 other population GWAS followed by the downstream analysis. GWAS, genome wide association

941 study; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFpEF, heart

942 failure with reduced ejection fraction; NIHF; non-ischemic heart failure; TWAS, transcriptome-

943 wide association study.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




944

945 **Fig. 2 | Prioritized genes.** (a) The odds ratios for HF development of the independent signals in
 946 the Japanese GWAS, cross-ancestry meta-analysis, and MTAG. The color of each point indicates
 947 the corresponding HF phenotype. The size of each point indicates $-\log_{10}(P)$ value). The shape of
 948 each point indicates the methods of analysis. The marker inside each point indicates novelty
 949 status. (b) Prioritized genes for each HF phenotype according to the types of analyses.

950 *CACNA1D* was prioritized in both BBJ and cross-ancestry meta-analysis and is shown in the
 951 “Meta-analysis” row. BBJ, BioBank Japan; HF, heart failure; HFpEF, heart failure with

952 preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; Meta, meta-
953 analysis; MTAG, multi-trait analysis of genome-wide association study; NIHF, non-ischemic
954 heart failure.



955

956


957

958

959


960

Fig. 3 | Pathway analysis for each HF phenotype. Enriched terms (FDR < 0.05) for each HF phenotype from GO, KEGG, PI, Reactome, and WP. Up to the top 20 enriched terms in each HF phenotype gene set are labeled. The color of the dots indicates the pathway. There was no enriched pathway for HFpEF. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PI, Pathway Interaction database; WP, Wiki Pathways.



961
 962 **Fig. 4 | Effects of common variants in cardiomyopathy genes on left ventricular function**
 963 **and long-term HF mortality. (a)** Minor allele frequency of lead SNPs in cardiomyopathy genes
 964 for East Asian and European populations according to gnomAD. **(b)** Effect size comparison of
 965 rs148116 (*TTN*) between BBJ and European for HFrEF. **(c)** Effects of lead variants in
 966 cardiomyopathy genes on LVEF in BBJ cohorts (left panel) and UKBB cohorts (right panel).
 967 Data are presented as estimated coefficients and their 95% confidence interval (CI). The shape of
 968 the points in c and d indicates the HF subtypes. Red points in c and d indicate statistically

969 significant effects. HF, heart failure; NIHF, non-ischemic heart failure. **(d)** Effects of lead
970 variants in cardiomyopathy genes for HF mortality among HF patients (indicated as circles, ICD-
971 10 I50, 326 deaths among 8,481 individuals) and non-HF individuals (indicated as squares, ICD-
972 10 I50, 749 deaths among 121,070 individuals). **(e)** Cumulative incidence curve for HF death
973 according to carriers of rs1484116 (*TTN*) in HF patients.



974

975 **Fig. 5 | Performance and clinical impact of the HF-PRS.** (a) Each point indicates

976 Nagelkerke's pseudo R^2 for all-cause HF case-control status in the Japanese independent cohort

977 (1,837 cases and 11,319 controls). PRS-derivation cohorts are indicated on the x-axis. (b)

978 Association between HF-PRS and onset age of HF. The onset age of HF in individuals with data

979 available ($n = 10,810$) is shown based on the HF-PRS tertiles. The number of individuals in each

980 tertile is 3,603 to 3,604. The center line of the box plot indicates the median, the bounds

981 represent the first and third quartile, and the whiskers reach to 1.5 times the interquartile range.

982 (c) Kaplan-Meier estimates of cumulative events from cardiovascular mortality (left) and HF
983 death (right) are shown with a band of 95%CI. Individuals are classified into high (top tertile),
984 intermediate (middle tertile), and low PRS (bottom tertile). P values were calculated for PRS by
985 Cox proportional hazard analysis and the significance was set at $P = 8.3 \times 10^{-3}$ (0.05/6).

Genome-wide analysis of heart failure enables polygenic and monogenic prediction of heart failure risks

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Table of Contents

Supplementary Notes	3
1. The SNP heritability and the liability-scale heritability	3
2. Replication of previously identified HF risk loci	3
3. Internal and external replication for novel loci found in BBJ GWAS	3
4. Cohorts used for cross-ancestry meta-analyses	4
5. Internal and external replication of cross-ancestry meta-analyses results .	5
6. Prioritization of rs10851802 in the cross-ancestry meta-analyses.....	5
7. Prioritized genes in MTAG	5
Supplementary methods	6
Cohort characteristics for BBJ 1st cohort and BBJ 2nd cohort	6
Cell type-specific heritability enrichment of disease associations	
using stratified LD score regression.....	7
Links between medication and prioritized loci	7
miRNA enrichment analysis.....	8
Heritability enrichment with scDRS	8
Supplementary Figures	9
Supplementary Fig. 1 Results of Japanese GWAS	9
Supplementary Fig. 2 Validation of previously identified loci using BBJ	10
Supplementary Fig. 3 Comparison of allele frequencies and	

26	allelic effects identified in Japanese GWAS	11
27	Supplementary Fig. 4 Downstream analysis of Japanese GWAS	13
28	Supplementary Fig. 5 Phenogram of genome-wide significant loci for HF	
29	and its subtypes	15
30	Supplementary Fig. 6 Results of the cross-ancestry meta-analysis	16
31	Supplementary Fig. 7 QQ plot and comparison of allele frequencies	
32	and allelic effects identified in the cross-ancestry meta-analysis	17
33	Supplementary Fig. 8 Downstream analysis of	
34	cross-ancestry meta-analysis	19
35	Supplementary Fig. 9 Results of multi-trait analysis of GWAS	21
36	Supplementary Fig. 10 Downstream analysis of	
37	multi-trait analysis of GWAS	23
38	Supplementary Fig. 11 Benn diagram for genes identified by each analysis ..	25
39	Supplementary Fig. 12 miRNA enrichment analysis and	
40	Single-cell enrichment analysis	26
41	Supplementary Fig. 13 Candidate drugs linked to disease	
42	susceptibility loci for HF.....	27
43	Supplementary Fig. 14 Analytical scheme for PRS development	28
44	Supplementary Fig. 15 PRS performance	29
45	Members of participating consortia	30
46	References	33

47

48 **Supplementary Notes**

49 **1. The SNP heritability and the liability-scale heritability**

50 The proportion of the variation in HF phenotypes (the single nucleotide polymorphism (SNP)
51 heritability; h^2) was estimated to be 1.5% (standard error of the mean [s.e.m.] 0.3%) for all-cause
52 HF, 1.5% (0.3%) for HF_{rEF}, 0.5% (0.3%) for HF_{pEF}, and 1.1% (0.3%) for NIHF using linkage
53 disequilibrium (LD)-score regression (LDSC). The liability-scale h^2 was estimated at 4.8%
54 (s.e.m. 1.0%) for all-cause HF, 12.6% (2.9%) for HF_{rEF}, 2.8% (1.7%) for HF_{pEF}, and 3.1%
55 (1.0%) for NIHF, suggesting the heterogeneous heritability in each HF phenotype.

56

57 **2. Replication of previously identified HF risk loci**

58 We assessed the 47 independent variants previously reported from all-cause HF GWAS¹, 13
59 variants from HF_{rEF} GWAS, one variant from HF_{pEF} GWAS², and one variant from NIHF³ in
60 our Japanese GWAS (BBJ). Out of 47 variants identified in the previous all-cause HF GWAS,
61 34 variants or variants tagged with the lead variant existed in BBJ, 28 had the same effect
62 direction, and 18 were nominally significant ($P < 0.05$; **Supplementary Fig. 2, Supplementary**
63 **Table 3**). Out of 13 variants identified in the European HF_{rEF} GWAS, 11 existed in BBJ, 10 had
64 the same effect direction, and 3 were nominally significant. The lead variant identified in the
65 European HF_{pEF} GWAS had the same direction and was nominally significant in BBJ, and the
66 lead or tagged variant identified in the European NIHF GWAS did not exist in BBJ.

67

68 **3. Internal and external replication for novel loci found in BBJ GWAS**

69 We sought to replicate the HF-risk loci that reached genome-wide significance in individual
70 GWAS cohorts. The effect size, direction (**Supplementary Fig. 3a**), and allele frequency of the

71 identified lead variants (**Supplementary Figure 3b**) were strongly concordant in BBJ 1st and
72 BBJ 2nd cohorts for all HF phenotypes (Pearson's correlation: all-cause HF 0.981; HFrEF 0.961;
73 HFpEF 0.752; NIHF 0.992). Three out of the five newly identified loci were nominally
74 significant in both BBJ 1st and BBJ 2nd cohorts (**Supplementary Fig. 3a** and **Supplementary**
75 **Table 4**). Out of the five newly identified loci, three loci identified in all-cause HF were found in
76 the European GWAS. rs35593046 were successfully replicated with nominal association ($P <$
77 0.05) with the same effect direction (**Supplementary Fig. 3c** and **Supplementary Table 5**). As
78 for rs6471480 and rs7075837, the same effect direction was observed in the European
79 population. rs76704104 identified in HFrEF and rs78228190 identified in HFpEF were not
80 observed in the European population according to the Genome Aggregation Database v4.0.0
81 (gnomAD) (<https://gnomad.broadinstitute.org/>).

82

83 **4. Cohorts used for cross-ancestry meta-analyses**

84 Cross-ancestry datasets (**Supplementary Table 18**) yielded 120,203 cases for all-cause HF
85 (BBJ: 16,251, EUR: 95,524, KADOORIE: 1,467, AMR: 1,170, AFR: 5,791), 23,749 cases for
86 HFrEF (BBJ 4,254, EUR: 19,495), 26,743 cases for HFpEF (BBJ: 7,154, EUR: 19,589), and
87 22,864 cases for NIHF (BBJ: 11,122, UKBB: 1,816, FinnGen: 9,926). The number of control
88 samples was 1,502,645 (BBJ: 197,577, EUR: 1,270,968, KADOORIE: 75,149, AMR: 13,217,
89 AFR: 20,883) for all-cause HF, 456,520 for HFrEF/HFpEF (BBJ: 197,577, EUR: 258,943), and
90 863,254 for NIHF (BBJ: 171,995, UKBB: 387,652, FinnGen: 303,607), respectively. We
91 included variants with $MAF \geq 1\%$ and tested a total of 11,119,536 variants for all-cause HF,
92 4,800,324 variants for HFrEF, 4,807,066 variants for HFpEF, and 4,998,828 variants for NIHF.

93

94 **5. Internal and external replication of cross-ancestry meta-analyses results**

95 The effect size and direction of the identified lead variants (**Supplementary Fig. 7b**)
96 were concordant in East Asians and Europeans for all HF phenotypes (Pearson's correlation: all-
97 cause HF 0.898; HFrEF 0.864; NIHF 0.983) except for HFpEF, for which Pearson's correlation
98 could not be calculated with significant loci < 3 .

99 To replicate lead variants of HFrEF and HFpEF using independent datasets, these were
100 assessed with European all-cause HF GWAS since there were no other available HFrEF/HFpEF
101 GWAS datasets. As for all-cause HF and NIHF, there was no dataset for external replication.
102 Effect sizes were generally concordant with Pearson's correlation of 0.817 in HFrEF
103 (**Supplementary Figure 7d and e**). The effect direction was also concordant in all of the three
104 novel loci (**Supplementary Table 21**). As for HFpEF, both significant variants were known HF-
105 related variants.

106

107 **6. Prioritization of rs10851802 in the cross-ancestry meta-analyses**

108 Among novel loci, we could not prioritize a gene for rs10851802. rs10851802 is linked to *GLCE*
109 according to the Open Targets database. rs10851802 was associated with rs2415040 ($r^2 = 0.548$),
110 which was a variant for lean mass⁴. Lean mass is associated with incident HF⁵. Although we
111 could not prioritize a gene in this locus, this evidence suggests that this locus was one of the
112 disease susceptibility loci. Further investigations were warranted to identify the candidate gene
113 in this locus.

114

115 **7. Prioritized genes in MTAG**

116 *BDNF* prioritized by PoPS (**Supplementary Table 40**) harbored pathogenic variants
117 responsible for obesity (**Supplementary Table 38**), and its knockout showed the same
118 phenotype (**Supplementary Table 39**). *MYBPC3* was one of the known cardiomyopathy genes
119 (**Supplementary Table 14, 38 and 39**), and this is the first report to show that common variants
120 of *MYBPC3* were associated with HF. *SLC4A7*, prioritized by PoPS (**Supplementary Table 40**),
121 was associated with abnormal vasoconstriction (**Supplementary Table 39**). Considering
122 *SLC4A7* splicing was enriched in fibroblasts (**Supplementary Figure 10b**), it suggested that
123 arterial fibroblasts contributed to HF through hypertension. Common variants in *PCSK1*
124 influenced blood pressure⁶, which was consistent with the fact that *PCSK1* was prioritized H-
125 MAGMA using the aorta Hi-C dataset (**Supplementary Fig. 10c**) and *PCSK1* knockout showed
126 obesity and hypertension (**Supplementary Table 39**). *PTPRJ* knockout showed abnormal
127 vascular development and abnormal heart development (**Supplementary Table 39**). *PLPP3* was
128 enriched in the fibroblasts in TWAS (**Figure 10a**), and its knockout caused the abnormal
129 vasculogenesis. These results were consistent with the previous report which indicated that
130 *PLPP3* regions was associated with hypertension⁷ and coronary artery disease⁸.

131 Among the novel loci, we could not assign a gene to rs10888955. This variant was
132 strongly associated with reticulocyte count⁹. Given that previous Mendelian randomization
133 analysis revealed the positive association of CAD with reticulocytes¹⁰, this locus could
134 contribute to HF development through CAD.

135

136

137 **Supplementary methods**

138 **Cohort characteristics for BBJ 1st cohort and BBJ 2nd cohort**

139 All subjects were Japanese and were registered in the BioBank Japan (BBJ) project
140 (<https://biobankjp.org/>). The BBJ is a hospital-based national biobank project that collects DNA
141 and serum samples and clinical information from 12 cooperative medical institutes throughout
142 Japan (Osaka Medical Center for Cancer and Cardiovascular Diseases, Cancer Institute Hospital
143 of Japanese Foundation for Cancer Research, Juntendo University, Tokyo Metropolitan Geriatric
144 Hospital, Nippon Medical School, Nihon University School of Medicine, Iwate Medical
145 University, Tokushukai Hospitals, Shiga University of Medical Science, Fukujuji Hospital,
146 National Hospital Organization Osaka National Hospital, and Iizuka Hospital). Approximately
147 267,000 patients with any of the 47 target diseases were enrolled from 2003 to 2007, and from
148 2013 to 2018. All subjects were at least 18 years old. Informed consent was obtained from all
149 participants, and our study was approved by the relevant ethical committee at each facility.

150

151 **Cell type-specific heritability enrichment of disease associations using stratified LD score** 152 **regression**

153 We applied stratified LD score regression (S-LDSC)¹¹ (v1.0.1. <https://github.com/bulik/ldsc>) to
154 the GWAS summary statistics of the cross-ancestry meta-analysis to evaluate the contribution of
155 genetic variation in cell type-specific genes to trait heritability. Heritability enrichment per cell
156 type was considered significant at $P < 7.2 \times 10^{-5}$ (0.05/694) based on the number of cell types
157 tested (694).

158

159 **Links between medication and prioritized loci**

160 We searched medications linked to prioritized genes using DrugBank and the Therapeutic Target
161 Database. Among medications with the same pharmacological actions, we chose a representative

162 one manually. The role of prioritized genes (e.g. protective or detrimental against HF) was
163 determined based on (1) knockout mice phenotyping or (2) the direction of TWAS Z-score if
164 knockout mice phenotyping was not reported to be associated with HF.

165

166 **miRNA enrichment analysis**

167 The overall polygenic contribution of miRNA–target gene network to the traits through the
168 tissue-naïve approach was estimated using MIGWAS software with default settings¹². The
169 significance threshold was set at 0.0125 based on the number of HF phenotypes (0.05/4).

170 Candidate miRNA-gene pairs were estimated by MIGWAS with a significance threshold set at
171 FDR < 0.05 for miRNA and genes.


172

173 **Heritability enrichment with scDRS**

174 To determine which cell types in hearts were enriched for HF GWAS, we used scDRS (v.1.0.2)¹³
175 with default settings. We used MAGMA v.1.10¹⁴ to map single-nucleotide polymorphisms to
176 genes (GRCh37 genome build from the 1000 Genomes Project) using an annotation window of
177 0 kb. We used the resulting annotations and GWAS summary statistics to calculate each gene's
178 MAGMA z score (association with a given trait). The 1,000 disease genes used for scDRS were
179 chosen and weighted based on their top MAGMA z scores. To determine trait association at the
180 annotated cell type resolution, we used the z scores computed from scDRS's downstream Monte
181 Carlo test. These Monte Carlo z scores were converted to theoretical P values using a one-sided
182 test under a normal distribution. The significance threshold was set at $P < 2.4 \times 10^{-3}$ based on
183 Bonferroni correction (0.05/21 based on the number of cell types).

184

185 **Supplementary Figures**



186

187 **Supplementary Fig. 1 | Results of Japanese GWAS. (a)** Sample overlap between each HF

188 phenotype in Japanese GWAS. **(b)** Miami plot for four HF phenotypes. $-\log_{10}(P)$ value on the y-


189 axis are shown against the genomic positions (hg19) on the x-axis. Association signals that

190 reached a genome-wide significance level ($P < 5 \times 10^{-8}$) are shown in red if new loci and in blue

191 if previously reported only in MTAG but not in GWAS. **(c)** QQ plot for each HF phenotype in


192 Japanese GWAS. Two-sided P values were calculated using a logistic regression model. GWAS,

193 genome-wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS.



194

195 **Supplementary Fig. 2 | Validation of previously identified HF loci in BBJ.** Comparison of
196 allelic effects (a) and allele frequency (b) between the previous GWAS and BBJ. Effect size with
197 its 95%CI or allele frequency of previous GWAS are shown in the x-axis, and those of BBJ are
198 shown in the y-axis.



199
200


201 **Supplementary Fig. 3 | Comparison of allelic effects and allelic effects identified in**

202 **Japanese GWAS.** (a and b) Comparison of allelic effects (a) and allele frequency (b) between
203 BBJ 1st and BBJ 2nd. Effect size with its 95%CI or allele frequency of BBJ 1st GWAS are shown
204 in the *x*-axis, and those of BBJ 2nd are shown in the *y*-axis. (c and d) Comparison of allelic
205 effects (c) and allele frequencies (d) between our Japanese GWAS (BBJ) and European GWAS.
206 Effect size and its 95%CI, or allele frequencies of BBJ are shown in the *x*-axis, and those of

207 European GWAS are shown in the y-axis. Points are shown in red if new loci and in blue if
208 previously reported only in MTAG but not in GWAS. CI, confidence interval; GWAS, genome-
209 wide association study; HF, heart failure; MTAG, multi-trait analysis of GWAS; QQ, quantile-
210 quantile.

211


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



212
 213 **Supplementary Fig. 4 | Downstream analysis of Japanese GWAS. (a)** Lead variants identified
 214 in our Japanese GWAS of each HF phenotype are searched in previously reported Japanese
 215 GWAS of cardiovascular-related phenotypes. The color indicates the Z value of the
 216 corresponding Japanese GWAS. **(b and c)** Lead variants identified by each HF phenotype
 217 Japanese GWAS are searched in GTEx eQTL **(b)** and sQTL **(c)**. The color indicates the Z value
 218 of the corresponding eQTL or sQTL. rs6596471, which was strongly correlated with lead variant
 219 chr5:138668504:T:C ($r^2 > 0.8$) is used as proxy variant since chr5:138668504:T:C was not found

220 in GTEx database. **(d)** Manhattan plots of H-MAGMA using aorta or adrenal gland Hi-C
221 datasets. $-\log_{10}(\text{FDR})$ on the y -axis are shown against the genomic positions (hg19) on the x -axis.
222 Genes that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are
223 shown in red. ** indicates novel loci, and * indicates loci previously reported only in MTAG and
224 not in GWAS. eQTL, expression quantitative trait loci; GWAS, genome-wide association study;
225 HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure
226 with reduced ejection fraction; H-MAGMA, Hi-C coupled MAGMA; LAA, left atrial
227 appendage; MTAG, multi-trait analysis of GWAS; NIHF; non-ischemic heart failure; sQTL,
228 splicing quantitative trait loci.
229

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




230


231 **Supplementary Fig. 5 | Phenogram of genome-wide significant loci for HF and its subtypes.**

232 Indicated gene names are the prioritized gene when one gene is prioritized by our methods, the
 233 nearest gene when multiple genes are prioritized equally, and the blank when none is prioritized
 234 and nearest gene is RNA gene. The shapes indicate HF subtypes; circles, all-cause HF;
 235 rectangles, HFrEF; triangles, HFpEF; and diamonds, non-ischemic HF. Colors indicate HF and
 236 its subtypes; red, BioBank Japan (BBJ); gray, European (EUR); light green, trans-ancestry meta-
 237 analysis (META); and black, multi-trait analysis of GWAS (MTAG). Cytobands and annotations
 238 are based on GRCh37/hg19. Gene names were annotated if prioritized by at least 3 methods.

239



240
241 **Supplementary Fig. 6 | Results of the cross-ancestry meta-analysis.** Miami plot of trans-
242 ancestry meta-analysis. $-\log_{10}(P)$ value on the y -axis is shown against the genomic positions
243 (hg19) on the x -axis. Association signals that reached a genome-wide significance level ($P < 5 \times$
244 10^{-8}) are shown in red if new loci and in blue if previously reported only in MTAG but not in
245 GWAS, genome-wide association study; HF, heart failure; HF_rEF, heart failure with
246 reduced ejection fraction; HF_pEF, heart failure with preserved ejection fraction; MTAG, multi-
247 trait analysis of GWAS.



248

249

Supplementary Fig. 7 | QQ plot and comparison of allele frequencies and allelic effects

250 **identified in the cross-ancestry meta-analysis. (a)** QQ plot for each HF phenotype in the cross-

251 ancestry meta-analysis. Two-sided P values were calculated using a logistic regression model. **(b)**


252 and **(c)** Comparison of allelic effects **(b)** and allele frequency **(c)** between East Asian GWAS and

253 European GWAS. Effect size with its 95%CI or allele frequency of East Asian (for all-cause HF)

254 or BBJ (other HF phenotypes) GWAS are shown in the x -axis, and those of European are shown

255 in the y -axis. **(d and e)** Comparison of allelic effects between the cross-ancestry meta-analysis


256 (HFrEF or HFpEF) and non-overlapping European GWAS (GBMI European all-cause HF).
257 Effect size with its 95%CI (**d**) or allele frequencies (**e**) of the cross-ancestry meta-analysis are
258 shown in the *x*-axis, and those of European GWAS are shown in the *y*-axis. Points are shown in
259 red if new loci and in blue if previously reported only in MTAG but not in GWAS. CI,
260 confidence interval; GWAS, genome-wide association study; HF, heart failure; HFrEF, heart
261 failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction;
262 MTAG, multi-trait analysis of GWAS; QQ, quantile-quantile.
263



264
265 **Supplementary Fig. 8 | Downstream analysis of the cross-ancestry meta-analysis. (a)**

266 Heatmap of the TWAS of HF (all-cause HF and HF subtypes) showing transcriptome-wide
267 significant associations with supporting evidence from colocalization. Colored squares TWAS
268 significant associations based on two-sided P values after multiple testing corrections ($P <$
269 1.55×10^{-6}). * indicate PP4 0.75-0.8, ** 0.8-0.9, *** 0.9-1.0. (b) Heatmap of the Splicing-
270 TWAS HF showing splicing-wide significant associations. Colored squares splicing-TWAS
271 significant associations based on two-sided P values after multiple testing corrections. Genes are

272 presented on the x -axis, and tissue types are on the y -axis in both **(a)** and **(b)**. **(c)** Manhattan plots
273 of MAGMA for all-cause HF, HF_{rEF}, and non-ischemic heart failure. $-\log_{10}(\text{FDR})$ on the y -axis
274 are shown against the genomic positions (hg19) on the x -axis. Genes that have not been
275 identified in previous TWAS, proteome-wide MR, or gene analysis are shown in red. HF, heart
276 failure; TWAS, transcriptome-wide association studies.
277



278

279 **Supplementary Fig. 9 | Results of multi-trait analysis of GWAS. (a)** Genetic correlation

280 between HF and cardiac MRI-derived parameters. Significant genetic correlations ($P < 0.05$) are

281 marked with an asterisk. Two-sided P values were calculated using linkage disequilibrium score

282 regression. **(b)** Miami plot of MTAG. $-\log_{10}(P)$ value) on the y -axis are shown against the


283 genomic positions (hg19) on the x -axis. Association signals that reached a genome-wide

284 significance level ($P < 5 \times 10^{-8}$) are shown in red if new loci. **(c)** QQ plot for each HF phenotype

285 in MTAG. GWAS, genome-wide association study; HF, heart failure; HFpEF, heart failure with

286 preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MTAG, multi-
287 trait analysis of GWAS; NIHF, non-ischemic heart failure; QQ, quantile-quantile.
288

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



289

290 **Supplementary Fig. 10 | Downstream analysis of multi-trait analysis of GWAS. (a)** Heatmap

291 of the TWAS showing transcriptome-wide significant associations with supporting evidence

292 from colocalization. Colored squares TWAS significant associations based on two-sided P


293 values after multiple testing corrections ($P < 1.55 \times 10^{-6}$). * indicate PP4 0.75-0.8, ** 0.8-0.9,

294 *** 0.9-1.0. **(b)** Heatmap of the Splicing-TWAS HF showing splicing-wide significant

295 associations. Colored squares splicing-TWAS significant associations based on two-sided P

296 values after multiple testing corrections. Genes are presented on the x -axis, and tissue types are

297 on the y -axis in both **(a)** and **(b)**. **(c and d)** Manhattan plots of MAGMA for all-cause HF or non-
298 ischemic heart failure **(c)**, and H-MAGMA using aorta Hi-C datasets in all-cause HF**(d)**. -
299 $\log_{10}(\text{FDR})$ on the y -axis are shown against the genomic positions (hg19) on the x -axis. Genes
300 that have not been identified in previous TWAS, proteome-wide MR, or gene analysis are shown
301 in red. HF, heart failure; TWAS, transcriptome-wide association studies.
302




303

304 **Supplementary Fig. 11 | Benn diagram for genes identified by each analysis. BBJ, BioBank**

305 **Japan; EUR, European; META, meta-analysis; MTAG, multi-trait analysis of GWAS.**

306



307

308 **Supplementary Fig. 12 | miRNA enrichment analysis and single-cell enrichment analysis.**


309 **(a)** MIGWAS results of the four HF phenotypes. The overall contribution of miRNA-target gene

310 network to the traits through the tissue-naïve approach. An enrichment signal is shown by -

311 $\log_{10}(P_{\text{MIGWAS}})$. **(b)** Heatmaps depicting each cell type-disease association for HF phenotypes.

312 Heatmap colors denote uncorrected P value of cell-type-disease association evaluated using

313 scDRS. Only significant associations are shown.




314

315 **Supplementary Fig. 13 | Candidate drugs linked to disease susceptibility loci for HF.** Dark

316 blue indicates HF subtypes; orange gene; purple medications; and brown diseases.

317

318




319

320 **Supplementary Fig. 14 | Analytical scheme for PRS development.** Schematic representation

321 for derivation, cross-validation, performance testing of HF-PRS in the independent test cohort,

322 and survival analysis for HF-PRS.

323



324

325 **Supplementary Fig. 15 | PRS performance. (a)** Pairwise comparison of PRS performance.

326 Distribution of the pairwise difference of Nagelkerke’s pseudo- R^2 (Δ pseudo- R^2 : Pseudo R^2_{Score}

327 $Y - \text{Pseudo } R^2_{Score} X$, X , and Y are found at the axis) between each pair of PRS models. The

328 distributions were obtained by bootstrapping 5.0×10^4 times. Two-sided bootstrap P values were

329 calculated by counting the number of Δ pseudo- $R^2 \leq 0$ or Δ pseudo- $R^2 > 0$ and then multiplying

330 the lower value by the minimum estimated P value ($2 * 1 / (5.0 \times 10^4) = 4 \times 10^{-5}$: two-sided).

331 The significance was set at $P = 5.0 \times 10^{-3}$ ($0.05/10$). **(b)** PRS distribution and HF prevalence.

332 Prevalence of HF based on the HF-PRS deciles in each combination of GWAS. The number of

333 individuals in each decile is 2,631-2,632. Data are presented as medians and 95% CI. PRS,

334 polygenic risk score; CI, confidence interval.

335 **Members of participating consortia**

336 **The Biobank Japan Project**

337 Koichi Matsuda^{1,2}, Takayuki Morisaki^{2,3}, Yukinori Okada⁴, Yoichiro Kamatani⁵, Kaori Muto⁶,
338 Akiko Nagai⁶, Yoji Sagiya², Natsuhiko Kumasaka⁷, Yoichi Furukawa⁸, Yuji Yamanashi³,
339 Yoshinori Murakami³, Yusuke Nakamura³, Wataru Obara⁹, Ken Yamaji¹⁰, Kazuhisa
340 Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Shinichi Higashiue¹⁴, Shuzo Kobayashi¹⁴,
341 Hiroki Yamaguchi¹⁵, Yasunobu Nagata¹⁵, Satoshi Wakita¹⁵, Chikako Nito¹⁶, Yu-ki Iwasaki¹⁷,
342 Shigeo Murayama¹⁸, Kozo Yoshimori¹⁹, Yoshio Miki²⁰, Daisuke Obata²¹, Masahiko
343 Higashiyama²², Akihide Masumoto²³, Yoshinobu Koga²³ & Yukihiro Koretsune²⁴

344

345 ¹Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The
346 University of Tokyo, Tokyo, Japan.

347 ²Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The
348 University of Tokyo, Tokyo, Japan.

349 ³The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

350 ⁴Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo,
351 Tokyo, Japan.

352 ⁵Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The University
353 of Tokyo, Tokyo, Japan.

354 ⁶Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo,
355 Japan.

356 ⁷Division of Digital Genomics, Institute of Medical Science, The University of Tokyo, Tokyo,
357 Japan.

358 ⁸Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo,
359 Tokyo, Japan.

360 ⁹Department of Urology, Iwate Medical University, Iwate, Japan.

361 ¹⁰Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of
362 Medicine, Tokyo, Japan.

363 ¹¹Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
364 Tokyo, Japan.

365 ¹²Division of Pharmacology, Department of Biomedical Science, Nihon University School of
366 Medicine, Tokyo, Japan.

367 ¹³Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon
368 University. School of Medicine, Tokyo, Japan.

369 ¹⁴Tokushukai Group, Tokyo, Japan.

370 ¹⁵Department of Hematology, Nippon Medical School, Tokyo, Japan.

371 ¹⁶Laboratory for Clinical Research, Collaborative Research Center, Nippon Medical School,
372 Tokyo, Japan.

373 ¹⁷Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.

374 ¹⁸Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.

375 ¹⁹Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

376 ²⁰The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

377 ²¹Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science,
378 Shiga, Japan.

379 ²²Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan.

380 ²³Iizuka Hospital, Fukuoka, Japan.

381 ²⁴ National Hospital Organization Osaka National Hospital, Osaka, Japan.

382

383 **References**

- 384 1. Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, Backman JD, Bellomo TR,
385 Bone WP, Biddinger KJ, Hui Q, Dikilitas O, Satterfield BA, Yang Y, Morley MP, Bradford Y,
386 Burke M, Reza N, Charest B, Regeneron Genetics C, Judy RL, Puckelwartz MJ, Hakonarson H,
387 Khan A, Kottyan LC, Kullo I, Luo Y, McNally EM, Rasmussen-Torvik LJ, Day SM, Do R,
388 Phillips LS, Ellinor PT, Nadkarni GN, Ritchie MD, Arany Z, Cappola TP, Margulies KB,
389 Aragam KG, Haggerty CM, Joseph J, Sun YV, Voight BF and Damrauer SM. Genome-wide
390 association and multi-trait analyses characterize the common genetic architecture of heart failure.
391 *Nat Commun.* 2022;13:6914.
- 392 2. Joseph J, Liu C, Hui Q, Aragam K, Wang Z, Charest B, Huffman JE, Keaton JM,
393 Edwards TL, Demissie S, Djousse L, Casas JP, Gaziano JM, Cho K, Wilson PWF, Phillips LS,
394 Program VAMV, O'Donnell CJ and Sun YV. Genetic architecture of heart failure with preserved
395 versus reduced ejection fraction. *Nat Commun.* 2022;13:7753.
- 396 3. Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi SH, Shoemaker MB, Haas
397 ME, Weng LC, Lindsay ME, Smith JG, Newton-Cheh C, Roden DM, London B, Investigators
398 G, Wells QS, Ellinor PT, Kathiresan S, Lubitz SA and Genetic Risk Assessment of Defibrillator
399 Events I. Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic
400 Discovery. *Circulation.* 2019;139:489-501.
- 401 4. Pei YF, Liu YZ, Yang XL, Zhang H, Feng GJ, Wei XT and Zhang L. The genetic
402 architecture of appendicular lean mass characterized by association analysis in the UK Biobank
403 study. *Commun Biol.* 2020;3:608.

- 404 5. Zhang L, Bartz TM, Santanasto A, Djousse L, Mukamal KJ, Forman DE, Hirsch CH,
405 Newman AB, Gottdiener JS and Kizer JR. Body Composition and Incident Heart Failure in
406 Older Adults: Results From 2 Prospective Cohorts. *J Am Heart Assoc.* 2022;11:e023707.
- 407 6. Gu Q, Yazdanpanah M, van Hoek M, Hofman A, Gao X, de Rooij FW and Sijbrands EJ.
408 Common variants in PCSK1 influence blood pressure and body mass index. *J Hum Hypertens.*
409 2015;29:82-6.
- 410 7. Donertas HM, Fabian DK, Valenzuela MF, Partridge L and Thornton JM. Common
411 genetic associations between age-related diseases. *Nat Aging.* 2021;1:400-412.
- 412 8. Koyama S, Ito K, Terao C, Akiyama M, Horikoshi M, Momozawa Y, Matsunaga H, Ieki
413 H, Ozaki K, Onouchi Y, Takahashi A, Nomura S, Morita H, Akazawa H, Kim C, Seo JS, Higasa
414 K, Iwasaki M, Yamaji T, Sawada N, Tsugane S, Koyama T, Ikezaki H, Takashima N, Tanaka K,
415 Arisawa K, Kuriki K, Naito M, Wakai K, Suna S, Sakata Y, Sato H, Hori M, Sakata Y, Matsuda
416 K, Murakami Y, Aburatani H, Kubo M, Matsuda F, Kamatani Y and Komuro I. Population-
417 specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci
418 for coronary artery disease. *Nat Genet.* 2020;52:1169-1177.
- 419 9. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM,
420 Tardaguila M, Huffman JE, Ritchie SC, Megy K, Ponstingl H, Penkett CJ, Albers PK, Wigdor
421 EM, Sakaue S, Moscati A, Manansala R, Lo KS, Qian H, Akiyama M, Bartz TM, Ben-Shlomo
422 Y, Beswick A, Bork-Jensen J, Bottinger EP, Brody JA, van Rooij FJA, Chitrala KN, Wilson
423 PWF, Choquet H, Danesh J, Di Angelantonio E, Dimou N, Ding J, Elliott P, Esko T, Evans MK,
424 Felix SB, Floyd JS, Broer L, Grarup N, Guo MH, Guo Q, Greinacher A, Haessler J, Hansen T,
425 Howson JMM, Huang W, Jorgenson E, Kacprowski T, Kahonen M, Kamatani Y, Kanai M,
426 Karthikeyan S, Koskeridis F, Lange LA, Lehtimaki T, Linneberg A, Liu Y, Lyytikainen LP,

427 Manichaikul A, Matsuda K, Mohlke KL, Mononen N, Murakami Y, Nadkarni GN, Nikus K,
428 Pankratz N, Pedersen O, Preuss M, Psaty BM, Raitakari OT, Rich SS, Rodriguez BAT, Rosen
429 JD, Rotter JI, Schubert P, Spracklen CN, Surendran P, Tang H, Tardif JC, Ghanbari M, Volker
430 U, Volzke H, Watkins NA, Weiss S, Program VAMV, Cai N, Kundu K, Watt SB, Walter K,
431 Zonderman AB, Cho K, Li Y, Loos RJJ, Knight JC, Georges M, Stegle O, Evangelou E, Okada
432 Y, Roberts DJ, Inouye M, Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS,
433 Ouwehand WH, Lettre G, Sankaran VG and Soranzo N. The Polygenic and Monogenic Basis of
434 Blood Traits and Diseases. *Cell*. 2020;182:1214-1231 e11.

435 10. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H,
436 Riveros-Mckay F, Kostadima MA, Lambourne JJ, Sivapalaratnam S, Downes K, Kundu K,
437 Bombá L, Berentsen K, Bradley JR, Daugherty LC, Delaneau O, Freson K, Garner SF, Grassi L,
438 Guerrero J, Haimel M, Janssen-Megens EM, Kaan A, Kamat M, Kim B, Mandoli A, Marchini J,
439 Martens JHA, Meacham S, Megy K, O'Connell J, Petersen R, Sharifi N, Sheard SM, Staley JR,
440 Tuna S, van der Ent M, Walter K, Wang SY, Wheeler E, Wilder SP, Iotchkova V, Moore C,
441 Sambrook J, Stunnenberg HG, Di Angelantonio E, Kaptoge S, Kuijpers TW, Carrillo-de-Santa-
442 Pau E, Juan D, Rico D, Valencia A, Chen L, Ge B, Vasquez L, Kwan T, Garrido-Martin D, Watt
443 S, Yang Y, Guigo R, Beck S, Paul DS, Pastinen T, Bujold D, Bourque G, Frontini M, Danesh J,
444 Roberts DJ, Ouwehand WH, Butterworth AS and Soranzo N. The Allelic Landscape of Human
445 Blood Cell Trait Variation and Links to Common Complex Disease. *Cell*. 2016;167:1415-1429
446 e19.

447 11. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh
448 PR, Lareau C, Shores N, Genovese G, Saunders A, Macosko E, Pollack S, Brainstorm C, Perry
449 JRB, Buenrostro JD, Bernstein BE, Raychaudhuri S, McCarroll S, Neale BM and Price AL.

- 450 Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell
451 types. *Nat Genet.* 2018;50:621-629.
- 452 12. Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C,
453 Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M,
454 Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M,
455 Yoshitomi H, Ito H, Ohmura K, AR RF, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani
456 Y, de Hoon M, Yamamoto K and Okada Y. Integration of genetics and miRNA-target gene
457 network identified disease biology implicated in tissue specificity. *Nucleic Acids Res.*
458 2018;46:11898-11909.
- 459 13. Zhang MJ, Hou K, Dey KK, Sakaue S, Jagadeesh KA, Weinand K, Taychameekiatchai
460 A, Rao P, Pisco AO, Zou J, Wang B, Gandal M, Raychaudhuri S, Pasaniuc B and Price AL.
461 Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-
462 seq data. *Nat Genet.* 2022;54:1572-1580.
- 463 14. de Leeuw CA, Mooij JM, Heskes T and Posthuma D. MAGMA: generalized gene-set
464 analysis of GWAS data. *PLoS Comput Biol.* 2015;11:e1004219.
465